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The emergence of HIV pre-exposure prophylaxis, applying antiretroviral drugs 
toward prevention of infection by human immunodeficiency virus in uninfected 
individuals, reveals a promising avenue toward decreasing the number of annual new 
HIV infections worldwide. The nucleotide reverse transcriptase inhibitor tenofovir, along 
with the nucleoside reverse transcriptase inhibitor emtricitabine, currently make up the 
FDA-approved regimen for pre-exposure prophylaxis. Intracellular phosphorylation of 
both tenofovir and emtricitabine is necessary to generate nucleotide triphosphate analogs 
that would competitively inhibit HIV reverse transcriptase.  
Kinases demonstrated to phosphorylate tenofovir to the intermediate tenofovir 
monophosphate and then to the active anabolite tenofovir monophosphate have been 
shown to be expressed in HIV-susceptible tissues. Adenylate kinase 2 phosphorylates 
tenofovir to tenofovir monophosphate in peripheral blood mononuclear cells, vaginal, and 
colorectal tissues. In colorectal tissues, creatine kinase, muscle was found to 
phosphorylate tenofovir monophosphate to tenofovir diphosphate. The two kinases 
pyruvate kinase, muscle and pyruvate kinase, liver and red blood cell were shown to yield 
tenofovir diphosphate in peripheral blood mononuclear cells and vaginal tissue. These 
four kinases were sequenced for genetic variants that could affect tenofovir activation. In 
a clinical study spread across the three geographic regions Bangkok, Thailand, Cape 
Town, South Africa, and New York City, USA, 103 previously unreported variants 
across the kinases AK2, CKM, PKM and PKLR were detected. Of 505 individuals, 19 
individuals (3.7% frequency) were found to be carrying variants that were predicted to be 
deleterious and probably damaging.  
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In emtricitabine activation, we put forward four candidate kinases that would 
yield the nucleotide triphosphate analog emtricitabine triphosphate. Emtricitabine 
requires three phosphorylation steps to become pharmacologically active. Deoxycytidine 
kinase and thymidine kinase 1 are proposed to phosphorylate emtricitabine to 
emtricitabine-monophosphate. To generate emtricitabine-diphosphate, cytidine 
monophosphate kinase 1 is suggested to phosphorylate emtricitabine-monophosphate. To 
form the competitive HIV reverse transcriptase inhibitor emtricitabine triphosphate, 
phosphoglycerate kinase 1 was identified as a candidate kinase. In a clinical study, we 
identified 17 previously unreported genetic variants of these kinases. 
 Additionally, to further understand tenofovir and emtricitabine disposition in 
tissue, a matrix-assisted laser desorption/ionization coupled to mass spectrometry method 
was developed. This method aims to image tenofovir, emtricitabine, and the 
corresponding phosphorylated anabolites of each drug in an effort to better understand 
drug distribution in HIV susceptible tissues.  
 Taken together, development of the imaging technology and application of next-
generation sequencing to identify variants in kinases proposed to activate nucleos(t)ide 
reverse transcriptase inhibitors aim to allow for explanations of inter-individual 




Doctoral advisor: Dr. Namandjé N. Bumpus 
Thesis readers:  Dr. Namandjé N. Bumpus  
   Dr. Amanda M. Brown 
Thesis committee:  Dr. Namandjé N. Bumpus 
   Dr. Amanda M. Brown 
Dr. Craig W. Hendrix 
   Dr. James T. Stivers 






I would like to thank to my advisor Dr. Namandjé N. Bumpus for her support during my 
study and research. Her feedback helped me during researching and writing this thesis.  
 
Besides Dr. Bumpus, I thank the rest of my thesis committee: Dr. Amanda M. Brown, Dr. 
Craig W. Hendrix, and Dr. James T. Stivers. I thank Dr. Brown for agreeing to be my 
thesis reader.  
 
Thanks also goes to my labmates in the Bumpus Lab: Dr. Julie Lade, Dr. Phil Cox, 
Carley Heck, and Dr. Erin Madeen.   
vi 
 
Table of Contents 
Title page           pg i 
Abstract           pg ii 
Acknowledgements          pg v 
Table of Contents         pg vi 
List of Tables          pg vii 
List of Figures          pg viii 
 
Chapter 1: Introduction         pg 1 
 References          pg 9 
 
Chapter 2: Discovery of genetic variants of the kinases that activate tenofovir among 
individuals from the United States, Thailand and South Africa   pg 13 
 References          pg 37 
 
Chapter 3: Identification of genetic variants discovered in candidate kinases involved in 
phosphorylation of tenofovir and emtricitabine.       pg 38 
 References          pg 62 
 
Chapter 4: Imaging tenofovir and tenofovir diphosphate using matrix assisted laser 
desorption ionization mass spectrometry imaging.     pg 64 
 References          pg 79 
 
Chapter 5: Conclusions……………………………………………………………….pg 84 




List of Tables 
Chapter 2: Discovery of genetic variants of the kinases that activate tenofovir among 
individuals from the United States, Thailand and South Africa. 
 Table 1. HPTN 067 participant enrollment location and gender information. pg 17 
Table 2. Previously unreported AK2 missense variants detected in clinical trial 
participants located in Bangkok, Thailand, Cape Town, South Africa, and New 
York City, 
USA…………………………………………………………………………..pg 24 
Table 3. Previously unreported CKM missense variants detected in clinical trial 
participants located in Bangkok, Thailand, Cape Town, South Africa, and New 
York City, USA. 
…………..……………………………………………………………..pg 26 
Table 4. Previously unreported PKM missense variants detected in clinical trial 
participants located in Bangkok, Thailand, Cape Town, South Africa, and New 
York City, USA. 
…………..……………………………………………………………..pg 28 
Table 5. Previously unreported PKLR missense variants detected in clinical trial 
participants located in Bangkok, Thailand, Cape Town, South Africa, and New 
York City, USA. 
…………..……………………………………………………………..pg 31 
 
Chapter 3: Identification of genetic variants discovered in candidate kinases involved in 
phosphorylation of tenofovir and emtricitabine. 
Table 1. Location and sex information of HPTN 069 participants who consented 
to genotyping……………………………………………………………..…..pg 45 
Table 2. AK2 missense variants detected in nine clinical trial participants.…pg 48 
Table 3. CKM missense variants detected in eight clinical trial participants...pg 49 
Table 4. PKM missense variants detected in 11 clinical trial participants…...pg 51 
Table 5. PKLR missense variants detected in seven clinical trial participants.pg 52 
Table 6. DCK missense variants detected in clinical trial participants across 
clinical research sites located in the United States…………………………...pg 54 
Table 7. CMPK1 missense variants detected in 34 clinical trial participants...pg 56 





Chapter 4: Imaging tenofovir and tenofovir diphosphate using matrix assisted laser 
desorption ionization mass spectrometry imaging. 





List of Figures 
Chapter 2: Discovery of genetic variants of the kinases that activate tenofovir among 
individuals from the United States, Thailand and South Africa. 
Figure 1. Distribution of individuals enrolled at the Bangkok study site carrying 
genetic variants in TFV-activating kinases…………………………………...pg 19 
Figure 2. Distribution of individuals enrolled at the New York City study site 
carrying genetic variants in TFV-activating 
kinases…………………………………...pg 20 
Figure 3. Distribution of individuals enrolled at the Cape Town study site with 
detectable genetic variants in TFV-activating kinases. ……………………....pg 21 
 
Chapter 3: Identification of genetic variants discovered in candidate kinases involved in 
phosphorylation of tenofovir and emtricitabine. 
Figure 1. Schematic showing proposed activation of FTC by nucleotide kinases. 
DCK and TK1 are hypothesized to phosphorylate FTC to FTC-MP………...pg 42 
Figure 2. Distribution of genetic variants in TFV-activating kinases across 30 
clinical trial participants………………………………………………………pg 47 
Figure 3. Distribution of individuals carrying genetic variants at the amino acid 
level in candidate kinases that phosphorylate FTC…………………………...pg 53 
 
Chapter 4: Imaging tenofovir and tenofovir diphosphate using matrix assisted laser 
desorption ionization mass spectrometry imaging. 
Figure 1. Total ion chromatogram fragmentation spectra of TFV at increasing 
normalized collision energies (NCE)…………………………………....……pg 71 
Figure 2. Distribution of TFV standard on a steel target plate using extracted ion 
MS/MS data.………………………………….........................................……pg 72 
Figure 3. Detection of TFV drug standard at different concentrations shows 
differences in intensity………………………………………………………..pg 73 
Figure 4. TFV distribution in a cervical biopsy is detected in a heterogeneous 
manner………………………………………………………….……………..pg 74 
Figure 5. TFV-DP fragmentation at normalized collision energies (NCE) of 15%, 
20%, and 22%.……...………………………………………….……………..pg 75 
Figure 6. TFV-DP drug standard on a steel target plate visualized using extracted 
ion MS/MS data. ...…………………………………………….………..……pg 76
1 
 
Chapter 1: Introduction 
 
I. HIV pre-exposure prophylaxis aims to reduce HIV incidence 
 Published in 2016, The World Health Organization Global AIDS Update reports 
over 36.7 million people worldwide living with human immunodeficiency virus (HIV) 
[1]. This takes into account the number of people living with HIV on antiretroviral 
therapy, however it also includes the up to 2.4 million new HIV infections reported in 
2015 alone. Over the past five years, the number of new HIV infections has not 
appreciably declined, remaining static around 2 million new infections since 2010 
worldwide [1]. In specific regions such as Eastern Europe and central Asia, this number 
has even doubled from 100,000 diagnoses in 2010 to 200,000 new diagnoses in 2015 [1]. 
Given this alarming and steady level of new infections, measures toward reducing the 
incidence of HIV infection are under active investigation. As the availability of 
antiretroviral therapies to HIV infected individuals has increased, the prevalence of HIV 
has as well. The number of HIV-infected individuals on antiretroviral therapy has more 
than doubled from 7.5 million people to 17.0 million since 2010 [1]. If the number of 
new infections per year does not decline, the prevalence of HIV worldwide will continue 
to rise.  
Interventions to reduce the incidence of HIV infection have included behavioral, 
surgical, and pharmacological approaches such as increased condom use [2], voluntary 
medical male circumcision [3, 4, 5], and prevention of mother-to-child transmission of 
HIV [6, 7] respectively. A pharmacological approach, prevention of mother-to-child 
transmission, implements antiretroviral drugs that have been previously used to treat 
individuals who have already been infected with HIV [6]. In an example employing this 
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strategy, the Breastfeeding, Antiretrovirals, and Nutrition study used antiretrovirals such 
as nevirapine, a non-nucleoside reverse transcriptase inhibitor, zidovudine, and 
lamivudine, both nucleoside reverse transcriptase inhibitors. These pharmacological 
agents were applied toward combatting infection of HIV in HIV-uninfected infants [6]. 
This study showed a 74% protection rate in infants who had been administered 
nevirapine and a 53% protection rate in infants whose mothers were on antiretroviral 
therapy [6].  
Administration of antiretrovirals for use against HIV infection has since been able 
to provide protection as post-exposure prophylaxis [8], as secondary prevention when 
given to HIV infected individuals [9], and as pre-exposure prophylaxis (PrEP) [10, 9]. 
Along with rates of protection from HIV infection in mother-to-child transmission 
studies, the rationale behind further investigation of PrEP lies within animal model 
studies. Several studies using macaque models and the antiretroviral nucleos(t)ide reverse 
transcriptase inhibitors tenofovir and emtricitabine indicate protection from HIV 
infection when either of these drugs are administered [11, 12, 13]. In one study, 
administration of either tenofovir alone or a combination of tenofovir and emtricitabine 
showed complete protection of macaques against simian-human immunodeficiency virus 
[12]. Supported by successful protection outcomes from mother-to-child transmission and 
macaque studies, PrEP was further investigated using tenofovir and emtricitabine in 
clinical trials that directly tested its efficacy.  
II. Tenofovir and emtricitabine are approved for use as PrEP 
 A form of chemoprophylaxis, PrEP is a strategy for HIV prevention in which an 
individual who is not infected with HIV is administered an oral or topical formulation of 
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an anti-HIV drug to protect themselves against HIV infection [14]. Currently, the only 
FDA-approved formulation of PrEP is Truvada ®, an oral coformulation of the 
nucleoside/nucleotide reverse transcriptase inhibitors tenofovir and emtricitabine [15, 
16].  
 Tenofovir and emtricitabine both mimic nucleosides/nucleotides that must be 
phosphorylated intracellularly to form their active metabolites [17, 18]. These 
phosphorylated metabolites are nucleoside/nucleotide triphosphate analogs that 
competitively inhibit HIV reverse transcriptase. Tenofovir is phosphorylated twice inside 
the cell to form tenofovir diphosphate [17], while emtricitabine is phosphorylated 
intracellularly three times to form emtricitabine triphosphate [18].  
Prior to its approval for use as PrEP in 2012, four clinical trials investigated 
tenofovir and emtricitabine. Testing either oral or topical administrations of drug, these 
studies were able to demonstrate protection from HIV infection. The largest study, 
monitoring 4,758 couples in Kenya and Uganda, showed a 75% rate of protection from 
HIV infection in subjects assigned to taking either tenofovir or tenofovir in conjunction 
with emtricitabine [19]. All couples participating in this study, known as Partners PrEP, 
were sero-discordant, with one partner infected with HIV and the other an HIV-
uninfected individual. The remaining three successful clinical trials examined populations 
of men who have sex with men in the iPrEx study [20], heterosexual men and women in 
the Botswana TDF2 study [21], and injection drug users in the Bangkok Tenofovir study 
[22, 23]. These studies showed 44%, 62%, and 49% reduction in HIV incidence 
respectively [20, 21, 23]. Taking adherence, measured by detection of tenofovir in 
participant plasma, into account, these statistics show greater rates of protection from 
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HIV infection. The Partners PrEP study exhibited 90% protection, iPrEx 92%, the 
Botswana TDF2 study 78%, and the Bangkok Tenofovir study 74% when examining 
participants with detectable tenofovir plasma levels [19, 20, 21, 23]. The increased rates 
of protection from HIV infection generated by these large-scale clinical trials across 
diverse populations resulted in the FDA’s approval of Truvada ® as PrEP in July 2012.  
Despite taking adherence into account when examining rates of PrEP efficacy 
across the four clinical trials, complete protection against HIV infection was not 
observed. Indeed, two clinical trials—FEM-PrEP and VOICE were unable to show 
protection from HIV infection in heterosexual women [24, 25]. Possible biological 
explanations for this show tenofovir levels ten-fold higher in rectal tissue than in vaginal 
tissue [26], indicating decreased protection by PrEP in women. These divergent outcomes 
call for further investigation of the disposition of tenofovir and emtricitabine to ensure 
complete efficacy of PrEP in all populations.  
 
 
III. Nucleotide reverse transcriptase inhibitors by are activated by nucleotide 
kinases 
Tenofovir requires two phosphorylation steps to form the competitive HIV 
reverse transcriptase inhibitor and nucleotide triphosphate analog, tenofovir diphosphate 
[17]. Tenofovir is first phosphorylated intracellularly to tenofovir-monophosphate [17]. 
Tenofovir-monophosphate then is phosphorylated to tenofovir-diphosphate (TFV-DP), 
which is the pharmacologically active form of TFV. Previous work done in our lab 
5 
 
interrogated this phosphorylation pathway, demonstrating not only the kinases involved 
in tenofovir activation, but also the compartment specificity of these kinases [27].   
Phosphorylation of tenofovir to tenofovir monophosphate has been observed from 
adenylate kinase 2 in vitro using purified protein from mouse and human cell lines [17, 
28]. In vivo, we have demonstrated phosphorylation of tenofovir by adenylate kinase 2 in 
peripheral blood mononuclear cells, vaginal, and colorectal tissues (Figure 1) [27]. 
Further, our lab has shown phosphorylation of tenofovir-monophosphate to tenofovir-
diphophate by creatine kinase, muscle in colorectal tissue [27]. Pyruvate kinase, muscle 
and pyrivate kinase, liver and red blood cell catalyze the phosphorylation of tenofovir-
monophosphate to tenofovir-diphosphate in peripheral blood mononuclear cells and 






Figure 1. Proposed sequence of tenofovir phosphorylation to form the active nucleotide 
triphosphate analog competitive inhibitor of HIV reverse transcriptase, taken from Lade 
et al. [27]  
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Emtricitabine, like tenofovir, is also nucleoside/nucleotide reverse transcriptase 
inhibitor that requires intracellular phosphorylation. In contrast to the monophosphate 
analog tenofovir, however, which needs to be phosphorylated twice, emtricitabine 
requires three phosphorylation steps to form nucleotide triphosphate analog necessary to 
inhibit HIV reverse transcriptase [18]. We thus put forward four candidate kinases that 
could activate emtricitabine in HIV susceptible tissues. Deoxycytidine kinase purified 
from calf thymus has demonstrated in vitro phosphorylation of emtricitabine to 
emtricitabine-monophosphate [18]. Thymidine kinase 1, another candidate kinase for 
emtricitabine phosphorylation has shown activity toward zidovudine and stavudine, 
nucleoside analogs that are structurally similar to emtricitabine [29]. Unlike 
emtricitabine, a cytidine analog, zidovudine and stavudine are thymidine analogs. 
However, all compounds are dideoxynucleosides, lacking both 2’- and 3’-hydroxyl 
groups in their sugar ring. Emtricitabine-monophosphate is proposed to be 
phosphorylated to emtricitabine-diphosphate from activity of the cytidine monophosphate 
kinase 1 toward lamivudine-monophosphate [30]. Lamivudine, like emtricitabine, is a 
cytidine analog. Differences between the structures of the two compounds are scarce, 
with the only difference being a fluorine atom in emtricitabine at the 5 position of the 
cytidine base. Phosphorylation of lamivudine-monophosphate to lamivudine diphosphate 
using purified human cytidine monophosphate kinase 1 has been demonstrated, 
indicating possible activity toward emtricitabine-monophosphate [30]. To form the 
pharmacologically active metabolite emtricitabine-triphosphate, we predict 
phosphoglycerate kinase 1 to demonstrate activity toward emtricitabine-diphosphate. 
This hypothesis stems from previously demonstrated phosphorylation of the anabolite of 
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the deoxynucleoside analog L-Fd4C [31]. Like lamivudine, this compound shares 
structural similarities with emtricitabine. Differing between L-Fd4C and emtricitabine is 
a double bond between the pentose 2’ and 3’ positions rather than a sulfur atom at the 3’ 
position found on emtricitabine. To demonstrate activity of phosphoglycerate kinase 1 
toward L-Fd4C, this kinase was purified from HepG2 cells [31]. 
 
IV. Pharmacogenetics may contribute to differences observed in PrEP outcomes 
 Despite taking into account participant adherence and demonstrating PrEP 
efficacy, prior PrEP clinical trials are unable to establish complete protection from HIV 
infection. Additional investigation of potential factors contributing to the divergent 
results of these clinical trials is necessary. One possible source of this divergence is the 
role of genetic variants in drug activation. Genetic variation in drug-metabolizing 
enzymes has been shown to play a role in inter-individual metabolism of and response to 
antiretrovirals [32].  
 Inter-individual genetic variation has been demonstrated in part in studies 
examining the pharmacokinetics of efavirenz, a non-nucleoside reverse transcriptase 
inhibitor [33, 34]. In a study comparing drug exposure in a black, non-Hispanic 
population and a European-American population, efavirenz was found to have a longer 
elimination half-life [33]. Geographic differences in efavirenz metabolism were also 
observed in another study, with individuals in Thailand and South Africa exhibiting 
lower clearance of efavirenz than in individuals in Europe or America [34].  
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 Studies carried out in our laboratory examining the anti-HIV drug maraviroc have 
demonstrated dissimilarities in drug metabolism among individuals exhibiting differing 
CYP3A5 genotypes [35]. In this pharmacokinetic study, maraviroc exposure was found 
to be reduced in individuals that were homozygous for the CYP3A5*1 allele [35]. This 
lower exposure, in comparison to individuals homozygous for the CYP3A5 wild-type 
allele, indicates maraviroc may be unsuitable for treatment against HIV in individuals 
homozygous for the CYP3A5*1 allele.  
 Unlike the efavirenz and maraviroc, tenofovir is not metabolized by any 
cytochrome P450 enzymes [36]. However, tenofovir must be activated intracellularly by 
kinases to form the nucleotide triphosphate analog that will competitively inhibit HIV 
reverse transcriptase. Given the evidence of inter-individual drug exposure previously 
discussed, one can envision the presence of genetic variants in kinases that activate 
tenofovir to play a role in tenofovir activation. A prior study in our lab has found 71 
previously unreported genetic variants in the genes that encode the kinases that have been 
found to phosphorylate tenofovir to tenofovir diphosphate [27]. These detected variants 
could negatively impact tenofovir activation, ultimately compromising the efficacy of 
HIV pre-exposure prophylaxis despite complete participant adherence.  
 
 
V. MALDI-MS Imaging informs spatial distribution of drug disposition 
The compartment specificity of tenofovir activation demonstrated in our previous 
work [27] and investigations of the efficacy of topical PrEP formulations [26, 37] require 
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a deeper understanding of tenofovir tissue pharmacokinetics. Compartments at risk for 
HIV infection such as rectal, vaginal, and cervical tissues [26, 37, 38, 39] have been 
interrogated for their concentration of tenofovir and its active anabolite tenofovir 
disphosphate. Using liquid chromatography coupled to tandem mass spectrometry, these 
studies have been helpful in confirming and measuring the amount of drug able to 
penetrate HIV-susceptible tissues, but are not able to provide any distribution or 
localization information. Because spatial distribution information is lost using this 
method, these studies have only been able to provide average quantifications of tenofovir 
and tenofovir diphosphate across the tissue sample. This method of quantification 
requires homogenization of the collected tissue sample, destroying any spatial 
distribution information available across tissue. In contrast to liquid chromatography-
tandem mass spectrometry techniques, spatial distribution of a drug can be preserved 
when using matrix assisted laser desorption/ionization coupled to imaging mass 
spectrometry (MALDI-IMS) [40]. Rather than necessitating the use of a homogenate, 
tissue can be analyzed in MALDI-IMS by way of tissue slices mounted on a glass slide. 
Because homogenization of tissue is not necessary for analysis using this method, 
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Chapter 2: Discovery of genetic variants of the kinases that activate tenofovir 
among individuals from the United States, Thailand and South Africa 
Abstract 
Tenofovir (TFV) is a nucleotide reverse transcriptase inhibitor approved for use in 
HIV pre-exposure prophylaxis (PrEP), a pharmacological approach to HIV prevention. 
TFV requires two phosphorylation steps to form a competitive inhibitor of HIV reverse 
transcriptase. The kinases adenylate kinase 2 (AK2), creatine kinase, muscle (CKM), 
pyruvate kinase, muscle (PKM) and pyruvate kinase, liver and red blood cell (PKLR) 
have been identified to phosphorylate tenofovir in peripheral blood mononuclear cells 
(PBMC), vaginal, and colorectal tissue. This study employed next-generation sequencing 
of genomic DNA isolated from 505 clinical trial participants in order to probe for variants 
of the genes encoding these kinases. Using bioinformatics tools, genetic variants 
predicted to impact TFV activation were identified in subjects across three geographic 
sites, namely Bangkok, Thailand, Cape Town, South Africa and New York City, USA. 
We identified 103 novel unreported variants across the kinases AK2, CKM, PKM and 
PKLR, with 19 of 505 individuals (3.7% frequency) carrying variants that were predicted 
to be deleterious and probably damaging. Investigating overlap of variants across the 
three geographic locations where sequencing for variants in AK2, CKM, PKM, and PKLR 
was carried out, 2 out of 19 AK2 variants were shared among individuals located in 
Bangkok and Cape Town, and in Bangkok and New York City. For PKLR, 1 out of 41 
variants were detected in both Cape Town and New York City. These data suggest that 
genetic variants exist in these populations that could potentially impact TFV 
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phosphorylation, contributing to variable outcomes in PrEP trials that cannot be 
explained by adherence alone.  
 
Introduction 
Tenofovir (TFV) is a nucleotide reverse transcriptase inhibitor currently used for 
the treatment and prevention of human immunodeficiency virus (HIV) infection [1]. In 
fact, Truvada ®, which is a combination of TFV and the nucleoside reverse transcriptase 
inhibitor emtricitabine is currently the only drug approved by the FDA for use in HIV 
pre-exposure prophylaxis (PrEP) [2]. PrEP is a pharmacological strategy for preventing 
HIV infection, the efficacy of which has been bolstered by 3 large-scale clinical trials 
including the iPrEX study comprised of 2,499 men who have sex with men (MSM) or 
transgender women (TGW) [3], the Botswana TDF2 study comprised of 1,219 men and 
women [4], and the Partners PrEP study, comprised of 4,747 serodiscordant couples [5]. 
Through examining significant populations at-risk for HIV infection, these trials 
demonstrated protection against HIV through daily oral administration of Truvada ®. 
When adjusted for adherence, 92% of MSM or TGW in the iPrEx study were observed to 
be protected from HIV infection in comparison to the placebo group [3]. The Botswana 
TDF2 study HIV-uninfected men and women, 78% of whom were protected against HIV 
when adjusted for adherence [4]. Finally, in the largest of these studies, Partners PrEP, a 
90% decrease in HIV infection among HIV-uninfected partners in comparison to placebo 
was observed [5]. However, despite taking adherence into account in the aforementioned 
studies, full protection against HIV was not demonstrated.  
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 In order to produce the active HIV reverse trancriptase inhibitor, TFV must be 
phosphorylated twice, first to tenofovir-monophosphate (TFV-MP) [6]. TFV-MP then is 
phosphorylated to tenofovir-diphosphate (TFV-DP), which is the pharmacologically 
active form of TFV. Our lab has investigated this phosphorylation pathway and 
demonstrated the compartment specificity of the kinases involved in TFV activation [7].  
Specifically, we found that adenylate kinase 2 (AK2) phosphorylates TFV to TFV-MP in 
peripheral blood mononuclear cells (PBMC), vaginal, and colorectal tissue. Interestingly, 
while we observed phosphorylation of TFV-MP to TFV-DP by creatine kinase, muscle 
(CKM) in colorectal tissue, the kinases pyruvate kinase, muscle (PKM) and pyruvate 
kinase, liver and red blood cell (PKLR) catalyzed this step in PBMC and vaginal tissue. 
Through this work, we proposed the possibility that genetic variants of these kinases 
could impact the kinase function and therefore TFV phosphorylation. In doing so, via 
genotyping 142 clinical trial participants across geographic regions located in the United 
States, South Africa and Uganda, we identified 71 previously unreported genetic variants 
in the genes encoding AK2, CKM, PKM, and PKLR. In the present study, we extend this 
work substantially through the analysis of genomic DNA isolated from 505 clinical trial 
participants across three geographic locations, namely Bangkok, Thailand (n = 171), New 
York City, USA (n = 149), and Cape Town, South Africa (n = 185). Of particular note, 
this study represents the first targeted resequencing analysis of the AK2, CKM, PKM, and 
PKLR genes in subjects in Asia. This work further establishes that genetic deficiencies in 






Materials and Methods  
Clinical study sites and sample collection. Dried blood spots (DBS) were obtained from 
HIV-uninfected individuals (n = 505) enrolled in the HIV Prevention Trials Network 
study HPTN 067 across three clinical research sites (CRS): Emavudleni CRS in Cape 
Town, South Africa; Silom Community Clinic CRS in Bangkok, Thailand, and the 
Harlem Prevention Center CRS (El-Sard CTU) in New York, United States. All 
participants sequenced consented to genetic testing. Every individual included in this 
study contributed five DBS, with each DBS containing 50 μL whole blood spotted onto 
WhatmanTM 903 Protein Saver Cards. Information about participants enrolled and 
genotyped in this study is summarized in Table 1. These participants were MSM or TGW 
and women who have sex with men (WSM) from three geographic locations.   
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HPTN 067 study locations and participant demographics n = 505 
 
Study site Reported gender n (% of n) 
Bangkok, Thailand MSM, TGW 171 (34) 
New York City, USA MSM, TGW 149 (30) 
Cape Town, South Africa WSM 185 (36) 
 
Table 1. HPTN 067 participant enrollment location and gender information.  
Study participants were enrolled across three geographic locations, with MSM and TGW 
enrolled in Bangkok (n = 171) and New York City (n = 149) and WSM enrolled in Cape 
Town (n = 185).  
 
Genomic DNA isolation from HPTN 067 DBS samples. Genomic DNA was isolated 
from 2 DBS from each individual using a QIAamp 96 DNA Blood Kit (QIAGEN, 
Valencia, CA). DBS were punched out using a hole puncher. Genomic DNA was 
extracted following the supplementary protocol “Isolation of genomic DNA from dried 
blood spots using the QIAamp ®96 DNA Blood Kit – (EN)” from QIAGEN. Purified 
DNA was eluted using 150 μL DEPC-treated, nuclease-free water (Quality Biological, 
Inc., Gaithersburg, MD) and concentrated using a ZR-96 DNA Clean-up KitTM (Zymo 
Research, Irvine, CA). Resulting concentrated and purified genomic DNA was eluted in 
12 μL DEPC-treated, nuclease-free water. 
 
Next-generation sequencing target design, sample preparation, and analysis. 
Sequencing of the kinases AK2, CKM, PKM and PKLR was executed using the Illumina 
TruSeq Custom Amplicon kit v1.5 (Illumina, San Diego, CA). Probes for sequencing the 
combination of these kinases were designed using Illumina DesignStudio software as 
previously described [7].Genomic DNA isolated from clinical samples was processed 
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following the Illumina TruSeq Custom Amplicon Library Preparation Guide (Part 
Number 15027983 Rev. C, August 2013). DNA concentration was measured using a 
Qubit ® 3.0 Fluorimeter (Thermo Scientific, New York, NY). Fifty ng of DNA input 
were used per DNA sample sequenced. The resulting prepared DNA library (6 µL) was 
diluted in 594 µL HT1 buffer containing 1% PhiX sequencing control. Illumina 
VariantStudio software was used to annotate and analyze variant read quality as 
previously described [7].  
Results 
 Geographic locations of clinical trial participants investigated for the presence of 
genetic variants. In order to probe the existence of variants in the genes that encode the 
kinases that activate TFV, DBS from 505 participants in Bangkok, Thailand, Cape Town, 
South Africa, and New York City, USA were investigated. Of the 505 participants 
sequenced for AK2, CKM, PKM, and PKLR in this study, 171 were located in Bangkok, 
Thailand, 149 were located in New York City, USA, and 185 were located in Cape 
Town, South Africa.  
 
Analysis of individuals carrying genetic variants in tenofovir-activating kinases 
AK2, CKM, PKM, and PKLR. To examine the presence of genetic variants in the 
nucleotide kinases reported to activate TFV, we employed a previously described 
targeted assay to sequence the exonic regions of the genes AK2, CKM, PKM and PKLR 
[7].  Further, we sequenced participants in each of the three geographic locations 
Bangkok (n = 171), New York City (n = 149), and Cape Town (n = 185) included in the 
HPTN 067 clinical study. Variant distribution among Bangkok study participants is 
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demonstrated using a Venn diagram in Fig. 1. At the Bangkok study site, 29 of the 171 
participants sequenced (17%, 29/171) for these kinases carried single nucleotide variants 
(SNVs) or deletions that were predicted to result in a mutation at the amino acid level. Of 
these 29 participants from the Bangkok study site, 26 individuals exhibited variants for a 
singular nucleotide kinase. Moreover, one individual had a variant detectable for only 
AK2, nine individuals had variants detectable for only CKM, eight individuals had 
variants detectable for only PKM, and eight individuals had variants detectable for only 
PKLR. Of the remaining three participants, one individual carried variants detectable in 
AK2 and PKM and two individuals had genetic variants in both PKM and PKLR.  
 
Figure 1. Distribution of individuals enrolled at the Bangkok study site carrying genetic 
variants in TFV-activating kinases. Each rectangle is representative of a TFV-activating 
kinase that was sequenced: AK2 in blue, CKM in pink, PKM in orange and PKLR in 
green. Numerical values indicate the number of individuals detected to carry a single 
nucleotide variation or deletion. Overlapping regions of each rectangle indicate the 
number of  individuals with genetic variants in more than one kinase.  
 
At the New York City study site, 35 of the 149 participants sequenced (23%, 
35/149) were observed to carry SNVs or deletions in predicted to result in a mutation at 
the amino acid level. The observed variant distribution among New York City study 
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participants is depicted using a Venn diagram in Fig. 2. Of the 35 participants from the 
New York City study site detected to carry a genetic variant, 27 exhibited variants for 
only one of the kinases sequenced. Six individuals carried variants for AK2 alone, seven 
individuals for CKM alone, six individuals for PKM alone, and eight individuals carried 
variants for PKLR alone. Further, of these 35 participants, eight carried genetic variants 
in more than one kinase. One individual was observed to have detectable variants in AK2, 
PKM, and PKLR, two individuals were observed to have detectable variants in AK2 and 
PKLR, two individuals were observed to have detectable variants in CKM and PKM and 
three individuals were observed to carry variants in PKM and PKLR.  
 
Figure 2. Distribution of individuals enrolled at the New York City study site carrying 
genetic variants in TFV-activating kinases. Each rectangle represents a TFV-activating 
kinase that was sequenced: AK2 in blue, CKM in pink, PKM in orange and PKLR in 
green. Numerical values in each compartment represent the number of individuals 
detected to have a single nucleotide variation or deletion. Overlapping regions of each 
rectangle indicate the number of individuals with genetic variants in more than one 
kinase.  
 
 Variant distribution among Cape Town study participants is shown using a Venn 
diagram in Fig. 3. Thirty of the 185 participants (16%, 30/185) enrolled at this study site 
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were observed to have SNVs or deletions predicted to result in a mutation at the amino 
acid level. Twenty-two individuals of the 30 individuals carrying variants in Cape Town 
exhibited single nucleotide variants for only one of the kinases sequenced. Of these 22 
individuals, two displayed variants in the kinase AK2 alone, seven in the kinase CKM 
alone, five in the kinase PKM alone, and eight in the kinase PKLR alone. In contrast to 
exhibiting variants in only one kinase, eight participants carried genetic variants in more 
than one kinase. Two individuals were observed to have detectable variants in AK2 and 
PKM. One individual was observed to have detectable variants in both AK2 and CKM. 
Seven individuals were observed to have detectable variants in only CKM, while two 
individuals were observed to have detectable variants in CKM and PKM and two 
individuals were observed to have detectable variants in CKM and PKLR. Five 
individuals were observed to have detectable variants in PKM. Eight individuals were 
observed to have detectable variants in PKLR. One individual was observed to carry 
detectable variants in PKM and PKLR.  
 
 
Figure 3. Distribution of individuals enrolled at the Cape Town study site with detectable 
genetic variants in TFV-activating kinases. Each rectangle represents a TFV-activating 
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kinase that was sequenced: AK2 in blue, CKM in pink, PKM in orange and PKLR in 
green. Numerical values in each compartment represent the number of individuals 
detected to have a single nucleotide variation or deletion. Overlapping regions of each 
rectangle indicate the number of individuals with genetic variants in more than one 
kinase.  
 
Investigation of AK2 genetic variants detected across three geographic locations. Our 
laboratory has previously demonstrated AK2 phosphorylation of TFV to TFV-MP in 
PBMC, vaginal tissue, and colon tissue. In the 505 participants sequenced in this study, 
we observed 17 single nucleotide variations (SNVs) predicted to result in a mutation of 
the amino acid sequence for the DNA reference sequence corresponding to AK2 
(NM_001625.3). These specific variants were detected across 16 individuals. The 
described variants, which include both previously reported and novel variants, are 
detailed in Supplementary Table 1. All 16 individuals were observed to be heterozygous 
for the variants detected. Further, of the 16 individuals observed to carry at least one 
SNV, two individuals were of the Bangkok study site, five individuals were of the Cape 
Town study site, and nine individuals were of the New York City study site. Among the 
individuals carrying at least one SNV, one individual at the Cape Town study site was 
observed to be carrying two variants while two individuals at the New York City study 
site were observed to be carrying two variants. Of the 17 AK2 genetic variants observed, 
13 of these variants, which were observed across 11 individuals, were previously 
unreported  (Table 2). Of the 505 individuals sequenced for AK2 missense variants, one 
individual in New York City was observed to have the previously unreported variant at 
the coding DNA position c.664G>A. Applying in silico functional prediction tools to the 
variant c.664G>A, it is predicted to be “deleterious” and “probably damaging”. In silico 
tools SIFT and PolyPhen were used to predict the functional consequences of these 
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variants as previously described [7].  Four variants contained in the Single Nucleotide 
Polymorphism database (dbSNP), were detected and are listed as follows: rs143825456 
(NM_001625.3:c.631G>A) was detected in two individuals, with one individual located 
in Bangkok and the other in Cape Town; rs148421308 (NM_001625.3:c.460G>A) was 
detected in one individual in New York City; rs61750965 (NM_001625.3:c.386G>A) 
was detected in one individual in New York City; rs12116440 




Table 2. Previously unreported AK2 missense variants detected in clinical trial 
participants located in Bangkok, Thailand, Cape Town, South Africa, and New York 
City, USA. 
Thirteen previously unreported genetic missense variants were detected in 11 individuals 
out of 505 individuals sequenced for the coding DNA reference sequence NM_001625.3.  
All individuals that had detectable variants were heterozygous for those variants. One 
individual from Cape Town had two detectable missense variants and one individual 
from New York City had two detectable missense variants. Across the three geographic 
locations where individuals were sequenced for AK2, one AK2 variant was found in both 
Bangkok and New York City but not in Cape Town.  
 
Investigation of sequence variants of CKM detected across three geographic 
locations. Because CKM has been shown to phosphorylate TFV-MP to TFV-DP in colon 
tissue, the existence of genetic variants in CKM predicted to yield functional effects on 
this kinase was investigated using a targeted next-generation sequencing assay. For the 
DNA reference sequence corresponding to CKM (NM_001824.4), 34 total variants 
comprised of SNVs and deletions that are predicted to be reflected in the amino acid 
sequence were detected across 30 individuals. The total observed variants, including 















Exon SIFT Prediction PolyPhen Prediction 
Bangkok T>C 699 616 206 I>V 6/6 tolerated(0.38) benign(0.063) 
Cape Town G>A 106 23 8 A>V 1/6 tolerated(0.27) benign(0.002) 
Cape Town T>C 166 83 28 K>R 1/6 deleterious(0) possibly_damaging(0.693) 
Cape Town G>A 247 164 55 A>V 2/6 deleterious(0) possibly_damaging(0.774) 
Cape Town C>T 258 175 59 E>K 2/6 tolerated(0.29) benign(0.01) 
Cape Town C>T 312 229 77 E>K 3/6 deleterious(0.01) possibly_damaging(0.656) 
New York 
City 
A>C 139 56 19 V>G 1/6 deleterious(0) possibly_damaging(0.882) 
New York 
City 
C>T 237 154 52 A>T 2/6 deleterious(0.01) possibly_damaging(0.859) 
New York 
City 
T>C 267 184 62 K>E 2/6 tolerated(0.59) benign(0.134) 
New York 
City 
C>T 546 463 155 E>K 5/6 tolerated(0.59) benign(0.187) 
New York 
City 
G>A 664 581 194 T>I 6/6 deleterious(0) probably_damaging(0.997) 
New York 
City 
T>C 699 616 206 I>V 6/6 tolerated(0.38) benign(0.063) 
New York 
City 
T>A 699 616 206 I>F 6/6 deleterious(0.03) benign(0.288) 
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1. Twenty-nine individuals were observed to be heterozygous for all the variants 
detected, while one individual in New York City was observed to be homozygous. Of the 
30 individuals observed to have detectable SNVs or deletions, nine individuals were 
located at the Bangkok study site, 12 individuals were located at the Cape Town study 
site, and nine individuals were located at the New York City study site. We observed two 
clinical trial participants exhibiting more than one variant for this kinase. One individual 
at the Bangkok study site was observed to carry two different variants and one individual 
at the Cape Town study site was observed to carry two variants. Twenty-six previously 
unreported single nucleotide variants or base deletions were detected across 24 
individuals (Table 3). Of the 505 individuals sequenced for CKM missense variants, nine 
individuals were observed to have a predicted “deleterious” and “probably damaging” 
variant, yielding a frequency of 1.8%. In silico tools SIFT and PolyPhen were used to 
predict the functional consequences of these variants. Five reported variants, found in the 
dbSNP, were detected and are listed as follows: rs149354459 (NM_001824.4:c.752G>A) 
was detected in one individual from Bangkok, rs17875625 (NM_001824.4:c.728G>T) 
was detected in one individual from Bangkok; rs201048164 (NM_001824.4:c.163G>A) 
was detected in one individual from Cape Town; rs17850202 (NM_001824.4:c.673T>C) 
was detected in one individual from New York City and rs11559024 






Table 3. Previously unreported CKM missense variants detected in clinical trial 
participants located in Bangkok, Thailand, Cape Town, South Africa, and New York 
City, USA. 
 
Twenty-six previously unreported genetic missense variants were detected in 24 
individuals out of 505 individuals sequenced for the coding DNA reference sequence 
NM_001824.4.  All individuals that had detectable missense variants were heterozygous 
for those variants. One participant from Bangkok had two missense variants and one 
participant from Cape Town had two missense variants. Across the three geographic 
locations evaluated for genetic variants for this kinase, no CKM variants were found in 















Exon SIFT Prediction PolyPhen Prediction 
Bangkok C>T 303 128 43 R>Q 2/8 tolerated(0.07) benign(0.288) 
Bangkok T>C 693 518 173 Y>C 5/8 deleterious(0) probably_damaging(0.991) 
Bangkok T>A 696 521 174 Y>F 5/8 tolerated(0.18) possibly_damaging(0.717) 
Bangkok T> C 713 538 180 T>A 5/8 deleterious(0) benign(0.086) 
Bangkok C> A 977 802 268 G>C 7/8 deleterious(0) possibly_damaging(0.822) 
Bangkok T> G 1262 1087 363 M>L 8/8 tolerated(0.35) benign(0.08) 
Cape Town G> C 451 276 92 I>M 3/8 deleterious(0) probably_damaging(0.951) 
Cape Town G> A 569 394 132 R>C 4/8 deleterious(0) probably_damaging(0.999) 
Cape Town C> T 623 448 150 E>K 4/8 deleterious(0.01) possibly_damaging(0.586) 
Cape Town C> T 638 463 155 E>K 4/8 deleterious(0) benign(0.177) 
Cape Town T> C 968 793 265 K>E 7/8 deleterious(0.04) possibly_damaging(0.568) 
Cape Town A> G 990 815 272 M>T 7/8 deleterious(0.05) possibly_damaging(0.503) 
Cape Town C> A 991 816 272 M>I 7/8 tolerated(0.05) benign(0.142) 
Cape Town T> A 995 820 274 N>Y 7/8 deleterious(0) probably_damaging(0.91) 
Cape Town C> A 1013 838 280 V>L 7/8 tolerated(0.18) benign(0.159) 
Cape Town T> A 1032 857 286 N>I 7/8 deleterious(0) probably_damaging(1) 
Cape Town C> G 1064 889 297 V>L 7/8 tolerated(0.21) benign(0.299) 
Cape Town G> T 1124 949 317 L>M 7/8 deleterious(0.02) probably_damaging(0.998) 
New York City C> A 392 217 73 G>C 3/8 deleterious(0) probably_damaging(0.997) 
New York City T> A 435 260 87 E>V 3/8 deleterious(0.02) benign(0.402) 
New York City T> A 482 307 103 T>S 3/8 tolerated(0.62) benign(0.001) 
New York City T> C 720 545 182 K>R 5/8 tolerated(0.11) benign(0.017) 
New York City A> T 806 631 211 W>R 5/8 deleterious(0) probably_damaging(0.994) 
New York City T> G 837 662 221 D>A 6/8 tolerated(0.08) benign(0.148) 
New York City A> G 924 749 250 F>S 6/8 deleterious(0) probably_damaging(1) 
New York City C> T 1172 997 333 V>I 8/8 tolerated(0.3) benign(0.085) 
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Investigation of sequence variants of PKM detected across three geographic 
locations. In PBMC and vaginal tissue, PKM has been shown to phosphorylate TFV-MP 
to TFV-DP. We employed a targeted next-generation sequencing assay to investigate the 
existence of genetic variants in PKM found in the exon regions of this kinase. For the 
DNA reference sequence corresponding to PKM (NM_001206796.1), 39 total variants 
comprised of SNVs and deletions that are predicted to be reflected in the amino acid 
sequence were detected across 33 individuals. The 39 observed variants, which include 
both previously reported and previously unreported variants, are listed in Supplementary 
Table 2. All 33 individuals carrying variants in PKM were observed to be heterozygous 
for all the described PKM variants. Of the 33 individuals observed to have detectable 
SNVs or deletions, 11 individuals were located at the Bangkok study site, 10 individuals 
were located at the Cape Town study site, and 12 individuals were located at the New 
York City study site. One individual at the Cape Town study site was observed to carry 
two variants. Two individuals at the New York City study site were observed to carry 
three variants. Thirty-three previously unreported single nucleotide variations or base 
deletions were detected across 29 individuals (Table 4). Three reported variants, found in 
the dbSNP, were detected and are listed as follows: rs141732747 
(NM_001206796.1:c.827C>A) was detected in one individual from New York City; 
rs185164430 (NM_001206796.1:c.1695C>G) was detected in one individual from New 
York City and rs778625515 (NM_001206797.1:c.132C>G) was detected in one 
individual from Cape Town. For the variants detected in PKM, functional predictions at 
the protein level were unavailable because the in silico tools, SIFT and Polyphen, were 
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unable to achieve sufficient sequence diversity information in the multiple alignments 



















Bangkok A>G 766 367 123 C>R 3/12 
Bangkok T>C 904 505 169 T>A 5/12 
Bangkok G>A 1007 608 203 T>I 6/12 
Bangkok T>C 1058 659 220 N>S 6/12 
Bangkok C>G 1399 1000 334 E>Q 7/12 
Bangkok C>T 1502 1103 368 R>H 8/12 
Bangkok G>A 1667 1268 423 A>V 9/12 
Bangkok C>T 1752 1353 451 M>I 9/12 
Bangkok T>C 1837 1438 480 T>A 10/12 
Bangkok A>G 2065 1666 556 W>R 11/12 
Cape Town  G>A 437 38 13 T>M 1/12 
Cape Town  G>C 617 218 73 A>G 3/12 
Cape Town  C>T 688 289 97 A>T 3/12 
Cape Town  A>T 850 451 151 S>T 4/12 
Cape Town  T>C 1027 628 210 K>E 6/12 
Cape Town  T>C 1412 1013 338 N>S 7/12 
Cape Town  T>C 1762 1363 455 I>V 10/12 
Cape Town  G>A 1792 1393 465 H>Y 10/12 
Cape Town  C>T 2122 1723 575 G>S 12/12 
Cape Town  G>T 2177 1778 593 S>Y 12/12 
New York City G>A 430 31 11 L>F 1/12 
New York City C>T 1345 946 316 A>T 7/12 
New York City T>C 1475 1076 359 E>G 8/12 
New York City T>A 1492 1093 365 M>L 8/12 
New York City T>C 1618 1219 407 S>G 9/12 
New York City C>T 1655 1256 419 G>D 9/12 
New York City T>A 1712 1313 438 E>V 9/12 
New York City C>A 1741 1342 448 A>S 9/12 
New York City A>T 1844 1445 482 L>H 10/12 
New York City C>T 1849 1450 484 E>K 10/12 
New York City A>G 1979 1580 527 V>A 11/12 
New York City C>T 2047 1648 550 D>N 11/12 
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Table 4. Previously unreported PKM missense variants detected in clinical trial 
participants located in Bangkok, Thailand, Cape Town, South Africa, and New York 
City, USA. 
Thirty-three previously unreported genetic missense variants were detected in 29 
individuals out of 505 individuals sequenced for the coding DNA reference sequence 
NM_001206796.1.  All individuals that had detectable variants were heterozygous for 
those variants. Across the three geographic locations evaluated for genetic variants for 
this kinase, no PKM variants were found in more than one geographic region. Using in 
silico tools PolyPhen and SIFT, no functional predictions were available for PKM.  
 
Investigation of sequence variants of PKLR detected across three geographic 
locations. PKLR has been shown to phosphorylate TFV-MP to TFV-DP in PBMC and 
vaginal tissue, leading us to investigate the existence of genetic variants in PKLR 
predicted to yield functional effects on this kinase. For the DNA reference sequence 
corresponding to PKLR (NP_000289.1), 39 total variants comprised of SNVs and 
deletions that are predicted to be reflected in the amino acid sequence were detected 
across 35 individuals. These observed variants are listed in Supplementary Table 2. 
Thirty-four individuals were determined to be heterozygous for the variants detected, 
with one individual identified as homozygous for one variant. Of the 34 individuals 
observed to have detectable SNVs or deletions, 10 individuals were located at the 
Bangkok study site, 11 individuals were located at the Cape Town study site, and 14 
individuals were located at the New York City study site. Two individuals at the Cape 
Town study site were observed to be carrying two variants compared to 4 individuals at 
the New York City study site that carried two variants. Thirty-one previously unreported 
single nucleotide variations or base deletions were detected across 26 individuals (Table 
5). One individual from Cape Town was homozygous for the variant G180V. All other 
participants that showed detected missense variants were heterozygous for the variants. 
One individual from Cape Town carried two missense variants and four individuals from 
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New York City had two missense variants. Across the three geographic locations 
evaluated for genetic variants in this kinase, no PKLR variants were found in more than 
one geographic region, however, in addition only two of the same variants were detected 
in more than one individual. Of the 505 individuals sequenced for PKLR missense 
variants, nine individuals were observed to have at least one predicted “deleterious” and 
“probably damaging” variant, yielding a frequency of 1.8% (9/585). In silico tools SIFT 
and PolyPhen were used to predict the functional consequences of these variants.  Six 
reported variants, found in the dbSNP, were detected and are listed as follows: 
rs147689373 (NM_000298.5:c.829G>A) was found in two individuals from New York 
City; rs116100695 (NM_000298.5:c.1456C>T) was found in one individual from New 
York City and one individual from Cape Town; rs189360283 
(NM_000298.5:c.1345C>T) was found in one individual from Cape Town; rs201979697 
(NM_000298.5:c.907C>T) was found in one individual from Cape Town; rs201406712 
(NM_000298.5:c.1435C>T) was found in one individual from New York City and 
rs150077703 (NM_000298.5:c.92C>A) was found in one individual from Bangkok. 
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Table 5. Previously unreported PKLR missense variants detected in clinical trial 
participants located in Bangkok, Thailand, Cape Town, South Africa, and New York 
City, USA. 
Thirty-one previously unreported genetic missense variants were detected in 26 


















Exon SIFT Prediction PolyPhen Prediction 
Bangkok G>A 89 50 17 S>F 1/11 deleterious(0) benign(0) 
Bangkok A>T 106 67 23 L>I 1/11 tolerated(0.06) benign(0.024) 
Bangkok C>T 161 122 41 R>Q 2/11 deleterious(0.01) benign(0.175) 
Bangkok G>C 302 263 88 T>S 2/11 tolerated(0.16) possibly_damaging(0.793) 
Bangkok G>C 368 329 110 A>G 3/11 deleterious(0) possibly_damaging(0.656) 
Bangkok A>T 1240 1201 401 C>S 8/11 deleterious(0.02) possibly_damaging(0.837) 
Bangkok A>G 1334 1295 432 V>A 9/11 deleterious(0) benign(0.062) 
Bangkok T>C 1652 1613 538 E>G 10/11 tolerated(0.11) benign(0.024) 
Cape Town C>T 375 336 112 M>I 3/11 deleterious(0.01) probably_damaging(1) 
Cape Town C>A 578 539 180 G>V 5/11 deleterious(0) probably_damaging(0.996) 
Cape Town G>T 947 908 303 P>Q 6/11 deleterious(0.05) benign(0.13) 
Cape Town C>T 1033 994 332 G>S 7/11 deleterious(0.01) probably_damaging(0.995) 
Cape Town A>G 1040 1001 334 M>T 7/11 deleterious(0.01) probably_damaging(0.995) 
Cape Town A>T 1091 1052 351 L>Q 7/11 deleterious(0) probably_damaging(0.992) 
Cape Town G>A 1313 1274 425 A>V 9/11 deleterious(0.01) benign(0.111) 
Cape Town C>T 1343 1304 435 R>Q 9/11 tolerated(0.63) benign(0.01) 
Cape Town T>A 1465 1426 476 T>S 9/11 tolerated(0.23) benign(0.002) 
Cape Town A>G 1576 1537 513 F>L 10/11 tolerated(0.25) possibly_damaging(0.624) 
New York City G>C 197 158 53 T>S 2/11 tolerated(0.47) benign(0.008) 
New York City G>T 368 329 110 A>D 3/11 deleterious(0) possibly_damaging(0.9) 
New York City A>G 460 421 141 F>L 4/11 tolerated(0.45) benign(0.082) 
New York City G>A 473 434 145 P>L 4/11 tolerated(0.1) possibly_damaging(0.653) 
New York City A>T 524 485 162 I>N 4/11 deleterious(0) probably_damaging(0.999) 
New York City G>A 530 491 164 T>I 4/11 deleterious(0.01) probably_damaging(1) 
New York City A>G 580 541 181 S>P 5/11 tolerated(0.26) benign(0.315) 
New York City A>T 866 827 276 V>E 6/11 deleterious(0) probably_damaging(0.986) 
New York City A>C 1230 1191 397 D>E 8/11 deleterious(0.01) possibly_damaging(0.872) 
New York City C>T 1234 1195 399 A>T 8/11 tolerated(0.29) probably_damaging(0.94) 
New York City G>A 1448 1409 470 A>V 9/11 deleterious(0.02) probably_damaging(0.995) 
New York City A>G 1520 1481 494 I>T 10/11 deleterious(0) probably_damaging(0.985) 




This study identified 103 previously unreported genetic variants of the kinases 
AK2, CKM, PKM, and PKLR in 505 clinical trial participants located in Thailand, Cape 
Town, and the United States. To increase confidence in the variants identified, our 
analyses conformed to the American College of Medical Genetics and Genomics clinical 
laboratory standards for next-generation sequencing [8]. This method of analysis has 
been previously described [7]. To compare frequencies in this study of previously 
reported genetic variants, data from the 1000 Genomes Project [9] and the Exome 
Aggregation Consortium (ExAC), which includes over 60,000 genotyped, unrelated 
individuals, [12] was used because of the population and, in the case of the 1000 
Genomes Project, location information these datasets provide.  
In comparison with a previous analysis from our laboratory that sequenced 142 
women from the geographic regions Durban, South Africa, Kampala, Uganda, and four 
locations within the United States [7], we detected one overlapping variant for the four 
kinases sequenced. Interestingly, this genetic variant for PKM SNP rs778625515 
(NM_001206796.1:c.354C>G) was detected in one clinical trial participant at the USA 
study site from our previous analysis and shared with one participant at the Cape Town 
study site in our current study. At the protein level, this PKM variant is predicted to result 
in a mutation from asparagine to lysine at amino acid residue 118 (N118K). This 
mutation is located adjacent to a beta strand comprised of amino acids 119 to 121  [10]. 
Because of its location two amino acids away from a reported ATP binding site, it is 
possible binding of this substrate will be disrupted, affecting kinase function; however, as 
noted above, the gene encoding PKM currently has no functional prediction of this 
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variant using in silico tools PolyPhen or SIFT. Functional predictions of the variants 
detected in PKM at the protein level were unavailable because the in silico tools used for 
prediction, SIFT and PolyPhen, were not supplied with sufficient sequence diversity 
required for the performed multiple sequence alignments necessary for the algorithms 
used in these predictions.  
 
Continuing the comparison to our previous study [7], the SNV rs147689373 
(NM_000298.5:c.829G>A) in the PKLR kinase was also detected in two individuals in 
the New York City study site we investigated. This yielded a 1.3% (2/149) frequency 
within New York City and a 0.40% (2/505) frequency in our study overall. This variant 
was also detected in one participant in South Africa in our previous study [7]. In the 1000 
Genomes Project, the overall frequency for this variant was 0.26%. The only location in 
the USA included in the 1000 Genomes Project reporting frequency was 0.78% in the 
Mexican Ancestry from Los Angeles USA. Remaining locations contributing to the 
overall frequency listed for this variant in the 1000 Genomes Project were 2.1% in 
African Caribbeans in Barbados, 1.0% Esan in Nigeria, 1.52% Luhya in Webuya Kenya, 
1.18% Mende in Sierra Leone, and 0.46% Yoruba in Ibadan, Nigeria. At the protein 
level, this variant results in a mutation at the 277th amino acid with a substitution from 
glutamic acid to lysine. Other previously reported variants around this region of the 




Of the previously reported variants detected in our study, the SNP in CKM 
rs11559024 (NM_001824.4:c.248A>G) was the only variant reported at an overall 
frequency greater than 1% across the ExAC database. This variant was detected in one 
individual from New York City, exhibiting a 0.20% (1/505) overall frequency across the 
three geographic locations in this study and a 0.67% (1/149) frequency in the New York 
City population we examined. Across data listed in the ExAC database, a total frequency 
of 1.1% throughout all the subpopulations included in the database is reported. All 
subpopulations exhibited frequencies of this variant, with Finnish European at 1.94%, 
non-Finnish European at 1.51%, South Asian at 0.58%, Other at 0.55%, Latino at 0.36%, 
African at 0.36%, and the East Asian population exhibiting 0.01% frequency. Consulting 
the 1000 Genomes Project, this variant is reported at the following frequencies in the 
following sites located in the USA: 0.25% in Utah Residents with Northern and Western 
European Ancestry, 0.49% in Gujarati Indians from Houston, Texas population, and 
0.78% in individuals reporting Mexican Ancestry from Los Angeles USA. Populations 
from the 1000 Genomes Project outside the United States showed frequencies at 0.58% in 
Bengali from Bangladesh, 0.49% in Han Chinese in Beijing, 0.53% in Colombians from 
Medellin, Colombia, 1.52% in Finnish in Finland, 1.65% in British in England and 
Scotland, 1.04% in Punjabi from Lahore, Pakistan, and 0.48% in Puerto Ricans from 
Puerto Rico. Overall, in the populations included in the 1000 Genomes Project combined, 
the frequency of this variant was 0.38%-- a higher overall frequency than that observed in 
our study. The resulting protein from this variant would exhibit a residue change at the 
83rd amino acid of the protein, resulting in the mutation of a glutamic acid to glycine. 
37 
 
Using in silico functional prediction tools, this substitution is predicted to be 
“deleterious” using the SIFT algorithm and “possibly damaging” using PolyPhen.  
 
 Possible effects on TFV activation by these variants can be envisioned by 
examining the resulting protein sequences. One example of a previously unreported 
deleterious and possibly damaging AK2 variant was found at the Cape Town study site, 
predicted to result in an amino acid substitution resulting in the mutation K28R. The 
protein position at 28 is reported to be in the middle of the ATP binding region of AK2 
[13]. This kinase, reported to catalyze the transfer of a phosphate group from an ATP 
molecule, would be functionally affected by this variant by having a disrupted source of 
phosphate to transfer onto TFV. This potential for binding disruption could impact TFV 
phosphorylation.  
 
The fact that we observed very little overlap between individuals in the variants 
identified suggests that while genetic differences in these kinases exist, the variants are of 
low frequency making the probability of detecting mutations that might impact TFV 
activation in a given population difficult to predict. Thus, genetic differences in TFV 
activation may be independent of one’s ethnicity or geographic origin.  Nevertheless, our 
results offer new, previously unreported variants across the AK2, CKM, PKM, and PKLR 
genes, which encode the kinases that play a role in tenofovir activation. Of note, several 
of these kinases were predicted to result in a loss or a decrease in the function of the 
protein. Taken together, this work lends further evidence to the possibility that genetic 
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variation in TFV activation may underlie clinically observed differences in efficacy that 
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Chapter 3:  
Identification of genetic variants discovered in candidate kinases involved in 
phosphorylation of tenofovir and emtricitabine. 
Abstract 
 
 Tenofovir (TFV) and emtricitabine (FTC) are the two components that make up the only 
drug currently approved by the FDA for HIV pre-exposure prophylaxis (PrEP). TFV and FTC are 
nucleoside mimics that must be phosphorylated to the nucleotide triphosphate analogs that 
competitively inhibit HIV reverse transcriptase. TFV activation by kinases adenylate kinase 2 
(AK2), creatine kinase, muscle (CKM), pyruvate kinase, muscle (PKM) and pyruvate kinase, 
liver and red blood cell (PKLR) has been demonstrated in peripheral blood mononuclear cells 
(PBMC), vaginal, and colorectal tissue, indicating compartment-specific phosphorylation of this 
compound. FTC requires three phosphorylation steps to form emtricitabine-triphosphate (FTC-
TP), with deoxycytidine kinase (DCK) and thymidine kinase 1 (TK1) proposed to phosphorylate 
FTC to emtricitabine-monophosphate (FTC-MP). Cytidine monophosphate kinase 1 (CMPK1) is 
suggested to phosphorylate FTC-MP to emtricitabine diphosphate (FTC-DP). Finally, 
phosphoglycerate kinase 1 (PGK1) is identified as a candidate for FTC-DP phosphorylation to the 
nucleotide triphosphate analog FTC-TP, the pharmacologically active competitive inhibitor of 
HIV reverse transcriptase. In this study, we apply next-generation sequencing toward identifying 
genetic variants in the genes encoding AK2, CKM, PKM, PKLR, DCK, TK1, CMPK1, and 
PGK1 in clinical samples from the HIV Prevention Trials Network study 069. We identified 17 
previously unreported genetic variants of these kinases. Using bioinformatics tools, se also put 
forth predictions of the functional impact of these genetic variants. Building upon previous 
studies, our results further push forward the concept that genetic variation may contribute to inter-






 The FDA’s approval of the combination antiretroviral therapy regimen Truvada ® for use 
as HIV pre-exposure prophylaxis (PrEP) in July 2012 remains a capstone in HIV prevention 
strategy as the first  approved pharmacological approach for preventing HIV infection in HIV 
uninfected individuals [1]. Playing an integral role toward FDA approval of Truvada ® as PrEP, 
the clinical trial iPrEX demonstrated 92% of men who have sex with men (MSM) or transgender 
women (TGW) were protected from HIV infection when adherent to the drug regimen [2]. PrEP 
as a strategy for HIV prevention was further supported by the Botswana TDF2 study, 
demonstrating 78% of HIV-uninfected men and women were protected against HIV infection [3], 
along with the Partners PrEP study, demonstrating 90% protection in sero-discordant couples [4]. 
In all of these studies, even when adherence was taken into account, full protection against HIV 
was not observed. We have previously put forth data through which we propose that this could 
occur at least in part, due to genetic variations in the activation of tenofovir (TFV), a component 
of the PrEP regimen Truvada ®, by kinases expressed in peripheral blood mononuclear cells 
(PBMC), vaginal tissue, and colorectal tissue [5]. 
 
Truvada ® is comprised of TFV, prescribed as the prodrug tenofovir disoproxil fumarate, 
and emtricitabine (FTC). Both compounds are nucleoside or nucleotide reverse transcriptase 
inhibitors (NRTIs). TFV is an adenosine monophosphate analog and FTC is a cytidine analog [6]. 
Both compounds consequently require intracellular phosphorylation to form their active 
nucleotide triphosphate analogs. To form the nucleotide triphosphate analog that competitively 
inhibits HIV reverse transcriptase, TFV must be phosphorylated twice. We have demonstrated 
adenylate kinase 2 (AK2) phosphorylation of TFV to tenofovir-monophosphate (TFV-MP) in 
PBMC, vaginal tissue, and colorectal tissue [5]. Interestingly, our lab found that phosphorylation 
of TFV-MP is compartment specific in that creatine kinase, muscle (CKM) can phosphorylate 
TFV-MP to TFV-DP in colon tissue, while pyruvate kinase, muscle (PKM) and pyruvate kinase, 
43 
 
liver and red blood cell (PKLR) were observed to catalyze the formation of  TFV-DP in PBMC 
and vaginal tissue [5]. Like TFV, FTC is also a NRTI that must be phosphorylated intracellularly 
to form FTC-TP. However, unlike the monophosphate analog TFV which needs to be 
phosphorylated twice, FTC requires three phosphorylation steps [7]. Consulting previous studies, 
we suggest four candidate kinases that could activate FTC in HIV susceptible tissues. 
Deoxycytidine kinase (DCK) has been shown in vitro to phosphorylate FTC to FTC-MP using 
calf thymus deoxycytidine kinase [7]. Another candidate kinase for phosphorylating FTC to FTC-
MP, thymidine kinase 1 (TK1), has been shown to phosphorylate zidovudine and stavudine [8]. 
Although zidovudine and stavudine are thymidine analogs rather than a cytidine analog, both are 
dideoxynucleosides as FTC is, with all compounds lacking both 2’- and 3’-hydroxyl groups in 
their sugar ring. Phosphorylation of FTC-MP to FTC-DP is hypothesized due to demonstrated 
activity of the kinase cytidine monophosphate kinase 1 (CMPK1) toward lamivudine 
monophosphate (3TC-MP) [9]. Lamivudine (3TC) is a cytidine analog structurally similar to 
emtricitabine, with the only difference between the two being a fluorine atom in emtricitabine at 
the 5 position of the cytidine base. A purified protein assay exhibited phosphorylation of 3TC-MP 
to lamivudine diphosphate (3TC-DP) using purified human CMPK1. Finally, to form the 
pharmacologically active metabolite FTC-TP, we predict phosphorylation of FTC-DP to FTC-TP 
by phosphoglycerate kinase 1 (PGK1). The basis for this prediction stems from previously 
demonstrated phosphorylation of the diphosphorylated anabolite of the deoxynucleoside analog 
L-Fd4C [10]. This compound is structurally similar to FTC, except for a double bond between the 
pentose 2’ and 3’ positions rather than a sulfur atom at the 3’ position that FTC exhibits. PGK1 






Figure 1. Schematic showing proposed activation of FTC by nucleotide kinases. DCK and TK1 
are hypothesized to phosphorylate FTC to FTC-MP. CMPK1 is suggested to phosphorylate FTC-
MP to FTC-DP. To form the nucleotide triphosphate analog FTC-TP, PGK1 is postulated to 
phosphorylate FTC-DP.  
 
 
Along with identifying TFV-activating kinases in PBMC, vaginal tissue, and colorectal 
tissue, previous work in our lab also put forth identification of previously unreported genetic 
variants in the kinases AK2, CKM, PKM, and PKLR [5]. Variants discovered in the previous 
study were predicted to have an impact on the function of the protein sequenced, exhibiting 
deleterious and damaging phenotype predictions. These functional predictions that could 
negatively affect TFV activation may provide an explanation for the incomplete protection 
against HIV despite adherence to PrEP.  
 
Our present study builds further upon the idea of genetic variation in drug activation 











phosphorylating kinases but also for the genes that encode DCK, TK1, CMPK1, and PGK1. 
Investigating the existence of genetic variants in these kinases could contribute to differences in 
HIV protection due to differences in inter-individual FTC phosphorylation. To test for the 
presence of such variants, we applied a targeted next-generation sequencing assay to sequence the 
genes AK2, CKM, PKM, PKLR, DCK, TK1, CMPK1, and PGK1 using genomic DNA isolated 
from whole blood. The clinical trial participants in this study were from the HIV Prevention 
Trials Network study HTPN 069. This work identifies previously unreported genetic variants in 
kinases that have been shown to activate TFV as well as in kinases predicted to activate FTC. 
Using in silico functional prediction tools, these variants were investigated for any possible 
functional effects on the expressed protein. Given the presence of variants that were predicted to 
impede protein function, it is possible that TFV phosphorylation and therefore activation becomes 
compromised in individuals carrying these variants. These findings expand the current knowledge 
of genetic variants that may contribute to differences in HIV protection, putting forward 
nucleotide kinases that may be involved in FTC activation and contributing elements other than 
adherence that may govern PrEP efficacy.  
 
Materials and Methods 
Clinical study sites and sample collection. Whole blood was obtained from HIV-uninfected 
individuals (n = 498) enrolled in the HIV Prevention Trials Network study HPTN 069 across 13 
clinical research sites (CRS) located within the United States: Bridge HIV CRS, San Francisco, 
CA (UCSF); Case CRS, Cleveland, OH (Case); Chapel Hill CRS, Chapel Hill, NC (UNC); 
Cornell CRS, New York, NY (Cornell); Fenway Health CRS, Boston, MA (Fenway); George 
Washington University CRS, Washington, DC (GW); Hospital of University of Pennsylvania, 
Philadelphia, PA (UPenn); Johns Hopkins University CRS, Baltimore, MD (JHU); New Jersey 
Medical School CRS, Newark, NJ (UMDNJ); Pitt CRS, Pittsburgh, PA (UPitt); Puerto Rico 
AIDS CRS, San Juan, PR (UPR); UCLA Care Center CRS, Los Angeles, CA (UCLA); 
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University of Washington AIDS CRS, Seattle, WA (UW). All participants sequenced consented 
to genetic testing. Information about participants genotyped in this study is summarized in Table 
1. These participants were MSM or TGW and women who have sex with men (WSM) in 




HPTN 069 Participants, n = 498     
Study Site Participant Sex  n 
Bridge HIV CRS, San Francisco, CA Female 0 
 Male 48 
Case CRS, Cleveland, OH Female 16 
 Male 33 
Chapel Hill CRS, Chapel Hill, NC Female 12 
 Male 28 
Cornell CRS, New York, NY Female 11 
 Male 22 
Fenway Health CRS, Boston, MA Female 13 
 Male 43 
George Washington University CRS, Washington, DC Female 19 
 Male 44 
Hospital of University of Pennsylvania, Philadelphia, 
PA Female 25 
 Male 11 
Johns Hopkins University CRS, Baltimore, MD Female 0 
 Male 21 
New Jersey Medical School CRS, Newark, NJ Female 26 
 Male 0 
Pitt CRS, Pittsburgh, PA Female 5 
 Male 23 
Puerto Rico AIDS CRS, San Juan, PR Female 14 
 Male 21 
UCLA Care Center CRS, Los Angeles, CA Female 2 
 Male 28 
University of Washington AIDS CRS, Seattle, WA Female 7 
  Male 26 
Table 1. Location and sex information of HPTN 069 participants who consented to genotyping.  
 
 
Genomic DNA isolation from HPTN 069 whole blood samples. Genomic DNA was isolated 
from 200 µL of whole blood from each individual using a QIAamp 96 DNA Blood Kit 
(QIAGEN, Valencia, CA). Genomic DNA was extracted following protocol “Purification of 
DNA from Whole Blood, 
Plasma, Serum, or Body Fluids – (EN)” from QIAGEN. Purified DNA was eluted using 150 μL 
DEPC-treated, nuclease-free water (Quality Biological, Inc., Gaithersburg, MD) and concentrated 
using a ZR-96 DNA Clean-up KitTM (Zymo Research, Irvine, CA). Resulting concentrated and 
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purified genomic DNA was eluted in 12 μL DEPC-treated, nuclease-free water. 
 
Next-generation sequencing target design, sample preparation, and analysis. Sequencing of 
the kinases that have been show to phosphorylate TFV to TFV-DP AK2, CKM, PKM and PKLR 
was executed using the Illumina TruSeq Custom Amplicon kit v1.5 (Illumina, San Diego, CA). 
To sequence the kinases proposed to phosphorylate FTC to FTC-TP, CMPK1, DCK, PGK1 and 
TK1, the Illumina TruSeq Custom Amplicon kit v1.5 was also used. Probes for sequencing the 
combination of these seven kinases were designed using Illumina DesignStudio software as 
previously described [5]. Genomic DNA isolated from clinical samples was processed following 
the Illumina TruSeq Custom Amplicon Library Preparation Guide (Part Number 15027983 Rev. 
C, August 2013). DNA concentration was measured using a Qubit ® 3.0 Fluorimeter (Thermo 
Scientific, New York, NY). A plasmid containing a known sequence for AK2 was used as an 
additional sequencing control. Fifty ng of DNA input were used per DNA sample sequenced. The 
resulting prepared DNA library (6 µL) was diluted in 594 µL HT1 buffer containing 1% PhiX 
sequencing control. Illumina VariantStudio software was used to annotate and analyze variant 





Analysis of individuals carrying genetic variants in tenofovir-activating kinases AK2, CKM, 
PKM, and PKLR. A targeted assay to sequence the exonic regions of the genes AK2, CKM, 
PKM, and PKLR was applied to investigate the presence of genetic variants in these nucleotide 
kinases. Across the United States, 13 clinical research sites recruited participants, resulting in 498 
total individuals (n = 498) who consented to genetic testing. Of these individuals, nine were 
observed to carry a single nucleotide variant in the AK2 gene, yielding a 1.8% frequency (9/498 
individuals) of AK2 variants within this population. One individual carrying one variant that was 
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predicted to be deleterious (0.2%, 1/498 individuals) was detected among the nine individuals 
with observed AK2 variants. In the CKM gene, 8 individuals were found to carry variants, 
showing 1.6% (8/498 individuals) of individuals carrying variants in this kinase. Of these 
individuals, five were predicted to carry deleterious variants, yielding a frequency of 1% (5/498 
individuals). The PKM gene sequenced across all individuals detected 11 participants to have 
variants (2.2% frequency, 11/498 individuals). The lack of sequence diversity required to perform 
the sequence alignments for this kinase did not allow for functional predictions using the in silico 
tools SIFT and Polyphen. Sequencing the kinase PKLR yielded 11 individuals predicted to carry 
genetic variants resulting in amino acid sequence alterations. All 11 individuals were observed to 
carry variants that were predicted to have a deleterious functional impact. These 11 individuals 
make up the observed frequency of 2.2% (11/498 individuals). Variant distributions of the 
tenofovir-activating kinases AK2, CKM, PKM, and PKLR in individuals are demonstrated using a 
Venn diagram in Figure 2.  
 
 
Figure 2. Distribution of genetic variants in TFV-activating kinases across 30 clinical 
trial participants. Each rectangle represents a nucleotide kinase that was sequenced, with 
AK2 in blue, CKM in pink, PKM in orange, and PKLR depicted in green. Numerical 
















or deletion. Overlapping regions of each rectangle indicate the number of individuals 
with genetic variants in more than one kinase. 
 
 
Analysis of AK2 genetic variants detected in nine clinical trial participants. In previous work, 
our laboratory has demonstrated AK2 to phosphorylate TFV to TFV-MP in PBMC, colon tissue, 
and vaginal tissue [5]. For the DNA reference sequence corresponding to AK2 (NM_001625.3), 
we observe two previously unreported variants and three previously reported variants. These five 
variants were detected across nine individuals (1.8% frequency, 9/498 individuals). Variants 
observed are shown in Table 2 and detailed in Supplementary Table 1. All individuals with 
detected variants were observed to be heterozygous for these variants. Both unreported variants 
were predicted to be tolerated, with one variant resulting in a N157S mutation and the other 
resulting in a P131T mutation at the protein level. Three variants previously listed in the Single 
Nucleotide Polymorphism database (dbSNP) were detected and are listed as follows: 
rs138577419 (NM_001625.3:c.49C>G) was detected in one individual, rs12116440  
 (NM_001625.3:c.625G>A) was detected in two individuals, with the variant rs61750965 
(NM_001625.3:c.386G>A) also observed in two individuals. Of the individuals exhibiting 
genetic variants for AK2, only one individual was observed to carry a predicted deleterious 
variant, resulting in a 0.2% frequency. 
 















Exon Sift PolyPhen dbSNP ID Variant Frequency 
T>C 553 470 157 N>S 5/6 tolerated(0.15) benign(0.001)  0.2% (1/498) 
G>C 132 49 17 R>G 1/6 deleterious(0) possibly_damaging(0.514) rs138577419 0.2% (1/498) 
C>T 708 625 209 A>T 6/6 tolerated(0.5) benign(0.056) rs12116440 0.4% (2/498) 
C>T 469 386 129 S>N 4/6 tolerated(0.49) benign(0.001) rs61750965 0.4% (2/498) 
G>T 474 391 131 P/T 4/6 tolerated(0.07) benign(0.037)  0.6% (3/498) 
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Identification of genetic variants in CKM gene yields variants in eight clinical trial 
participants. TFV-MP must be phosphorylated to TFV-DP to become the active competitive 
inhibitor of HIV reverse transcriptase. We have demonstrated that in colon tissue, CKM 
phosphorylates TFV-MP to TFV-DP, generating the pharmacologically active reverse 
transcriptase inhibitor. Comparison to the DNA reference sequence for CKM (NM_001824.4), 
through sequencing the exon region of this gene yielded four previously unreported variants and 
two variants found in the SNP database. These six variants were detected across eight individuals, 
presenting a 1.6% (8/498) frequency of individuals carrying variants. Further details regarding 
these variants are in Table 3 and Supplementary Table 2. All individuals with CKM genetic 
variants were observed to be heterozygous for those variants. The four previously unreported 
variants resulted in a predicted deleterious T35I protein mutation, a predicted deleterious T53N 
mutation, and two predicted tolerated mutations at R43Q and G4C. Of the six variants detected 
for CKM in this population, two were found in dbSNP. The variant rs149354459 
(NM_001824.4:c.752G>C) was observed in one individual, while the variant rs11559024 
(NM_001824.4:c.248A>G) was observed in two individuals. Across all variants detected in the 
CKM gene sequenced, five individuals exhibited variants that were predicted to be deleterious 
(1% frequency, 5/498). 
  














Exon Sift PolyPhen dbSNP ID Variant 
Frequency 
G>A 279 104 35 T/I 2/8 deleterious(0) probably_damaging(0.914) 
 
0.2% (1/498) 
C>G 927 752 251 R/P 6/8 tolerated(0.09) benign(0.129) rs149354459 0.2% (1/498) 
T>C 423 248 83 E/G 3/8 deleterious(0.01) possibly_damaging(0.467) rs11559024 0.6% (3/498) 
C>T 303 128 43 R/Q 2/8 tolerated(0.07) benign(0.288) 
 
0.2% (1/498) 
C>A 185 10 4 G/C 2/8 tolerated(0.1) probably_damaging(0.998) 
 
0.2% (1/498) 
G>T 330 155 52 T/N 2/8 deleterious(0.04) probably_damaging(0.972)   0.2% (1/498) 
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PKM genetic variants observed in 11 clinical trial participants. Our laboratory has previously 
demonstrated phosphorylation of TFV-MP to TFV-DP by PKM in PBMC and vaginal tissue [5]. 
In the 498 participants sequenced for the DNA reference sequence corresponding to PKM 
(NM_001206796), 11 individuals were found to carry variants at the amino acid level (2.2% 
frequency, 11/498). Across these 11 individuals, five total variants were observed, with three 
previously unreported variants and two variants found in the SNP database. These variants are 
presented in Table 4 and detailed in Supplementary Table 3. Variants detected in PKM did not 
have functional predictions at the protein level because the in silico prediction tools PolyPhen and 
SIFT did not have sufficient sequence diversity information in the multiple alignments used to 
predict variant functional impact. The two previously reported genetic variants for PKM were 
rs180716407 (NM_001206796.2:c.14C>G) and rs201533100 (NM_001206796.2:c.395T>C). The 
variant rs180716407 was detected in five individuals while the variant rs201533100 was detected 




Table 4. PKM missense variants detected in 11 clinical trial participants .  
 
Examination of PKLR genetic variants detected in seven clinical trial participants. TFV-MP 
phosphorylation by the kinase PKLR been demonstrated in PBMC and vaginal tissue [5]. For the 
DNA reference sequence corresponding to PKLR (NM_000298.5), five variants comprised of 
SNVs and deletions that are predicted to be reflected in the amino acid sequence were detected 
across seven individuals. These variants are shown in Table 5, with further information available 
in Supplementary Table 4. Two previously unreported variants were predicted to have a 
deleterious impact on protein function. The amino acid substitution of tryptophan for glycine at 
the protein position 406 is predicted to be deleterious as is the previously unreported N133K 
mutation at the protein level. Of the five variants detected in this population, three had been 
previously reported and are in the dbSNP. The variant rs147659527 (NM_000298.5:c.814C>G) 
was detected in two individuals as was the variant rs61755431 (NM_000298.5:c.1706G>A). The 
variant rs116100695 (NM_000298.5:c.1456C>T) was detected in one individual. Of all the 
individuals carrying variants in the PKLR gene, all 7 individuals are predicted to be carrying 
deleterious variants. This results in a 1.4% frequency (7/498) of individuals exhibiting deleterious 
variants.  
  








Exon dbSNP ID Variant 
Frequency 
G>G/T 931 532 178 L/I 5/12   0.4% (2/498) 
G>G/C 413 14 5 S/* 1/12 rs180716407 0.6% (3/498) 
T>T/A 505 106 36 T/S 2/12 rs147562047 0.2% (1/498) 
A>A/G 794 395 132 V/A 4/12 rs201533100 0.2% (1/498 
T>T/A 505 106 36 T/S 2/12 rs147562047 0.2% (1/498 
G>G/T 770 371 124 T/N 3/12  
0.2% (1/498 






Table 5. PKLR missense variants detected in seven clinical trial participants.  
 
Analysis of individuals carrying genetic variants in candidate emtricitabine-activating 
kinases CMPK1, DCK, PGK1, and TK1. FTC is an NRTI cytidine analog that must be 
phosphorylated intracellularly to FTC-MP, FTC-DP, and finally FTC-TP to form the active 
triphosphate that inhibits HIV reverse transcriptase. We investigated the presence of genetic 
variants predicted to be present at the amino acid level in the kinases CMPK1, DCK, PGK1, and 
TK1 in 498 clinical trial participants across 13 clinical research sites in the United States. Of these 
498 individuals, 34 exhibited variants in CMPK1, 11 exhibited variants in DCK, and 2 individuals 
displayed variants for the PGK1 gene. The 33 individuals with detected variants in CMPK1 
indicate a 6.8% (34/498) frequency of individuals carrying variants in this population. For the 
DCK gene, 12 individuals carrying variants yielded a 2.4% (12/498) frequency. In PGK1, two of 
498 individuals exhibited variants in this gene (0.4% frequency, 2/498 individuals).The kinase 
TK1 did not have any individuals with variants detected to affect the amino acid level of this 
protein. Distribution of variants among individuals is depicted in a Venn diagram in Figure 3. 
Within this population, three clinical trial participants exhibited variants in more than one kinase. 
CMPK1 and DCK variants were detected in 2 individuals, while one individual exhibited variants 











Exon Sift PolyPhen dbSNP ID Variant 
Frequency 
C>C/A 1255 1216 406 G/W 8/11 deleterious(0) probably_damaging(1)   
0.2% (1/498) 
G>G/C 853 814 272 L/V 6/11 deleterious(0) probably_damaging(0.974) rs147659527 
0.2% (1/498) 
C>C/T 1745 1706 569 R/Q 11/11 deleterious(0.04) benign(0.399) rs61755431 
0.4% (2/498) 
G>G/C 853 814 272 L/V 6/11 deleterious(0) probably_damaging(0.974) rs147659527 
0.2% (1/498) 
G>G/T 438 399 133 N/K 4/11 deleterious(0.03) probably_damaging(0.999)  
0.2% (1/498) 





Figure 3. Distribution of individuals carrying genetic variants at the amino acid level in 
candidate kinases that phosphorylate FTC. Each circle represents a nucleotide kinase that 
was sequenced, with CMPK1 in blue, DCK in red, and PGK1 in yellow. Numerical 
values indicate the number of individuals detected to carry a single nucleotide variation 
or deletion. Overlapping regions of each circle indicate the number of individuals with 
genetic variants in more than one kinase. 
 
 
Investigation of DCK genetic variants observed in 12 clinical trial participants. DCK has 
been reported to show activity toward deoxycytidine analogs (thymidine kinase and 
deoxycytidine kinase in HIV-infected children) [7] [8], rendering this kinase a prospective 
activator of FTC, a cytidine analog. Given the reported activity of DCK on deoxycytidine analog, 
one can envision possible activity of this kinase toward the cytidine analog FTC. In the 498 
individuals sequenced for the kinase DCK (NM_000788.2), 12 individuals were detected to carry 
five unique genetic variants predicted to affect translation at the amino acid level of this gene. All 
individuals carrying variants exhibited heterozygosity for these SNVs. The variants detected are 
shown in Table 6, with  further detail found in Supplementary Table 5. Of these six genetic 
variants, two variants were previously unreported, with one variant with the protein mutation 
S93F predicted to be deleterious and the other variant resulting in a stop codon. The three 










rs67437265 (NM_000788.2:c.364C>T) was detected in six individuals, rs66878317 
(NM_000788.2:c.70A>G) was detected in one individual, and the SNP rs144479260 
(NM_000788.2:c.261G>A) was detected in one individual. Across all individuals carrying 
variants for DCK, only one individual presented a variant predicted to be deleterious, resulting in 
a 0.2% (1/498) frequency.  
 
Table 6. DCK missense variants detected in clinical trial participants across clinical research sites 
located in the United States.  
 
TK1 genetic variants detected in five clinical trial participants did not result in amino acid 
changes. In this study, no exonic, or missense variants for TK1 (NM_003258.4) were detected in 
any clinical trial participants. However, a previously reported intron variant rs2661681 
(NM_003258.4:c.394-4G>A) was detected in five individuals, yielding a 1% (5/498) frequency 
for the only variant detected for this kinase in this study. Because this variant is in the intron, 
there was no functional impact prediction available.  
 
Examination of CMPK1 genetic variants detected in 34 clinical trial participants. CMPK1 
has been shown to phosphorylate 3TC-MP, a monophosphorylated cytidine analog to 3TC-DP 
[9]. Similarities in 3TC and FTC structure indicate CMPK1 as a kinase with prospective activity 
toward phosphorylating FTC-MP to FTC-DP. Using the reference DNA sequence NM_016308.2 
for CMPK1, seven variants across 34 individuals were detected. All individuals were 
heterozygous for the variants they exhibited. These variants are shown in Table 7 and with further 











Exon Sift PolyPhen dbSNP ID Variant Frequency 
C>C/T 652 364 122 P/S 3/7 tolerated(0.06) probably_damaging(1) rs67437265 0.4% (2/498) 
C>C/T 566 278 93 S/F 3/7 deleterious(0) probably_damaging(0.969)  0.2% (1/498) 
A>A/G 358 70 24 I/V 1/7 tolerated(0.65) benign(0.002) rs66878317 0.2% (1/498) 
C>C/T 652 364 122 P/S 3/7 tolerated(0.06) probably_damaging(1) rs67437265 0.8% (4/498) 
G>G/T 739 451 151 E/* 4/7    0.6% (3/498) 
G>G/T 549 261 87 E/D 3/7 tolerated(0.61) benign(0) rs144479260 0.2% (1/498) 
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unreported. An unreported variant translating to an arginine to serine mutation at the 74 protein 
position was predicted to be deleterious, with one individual exhibiting this variant. A second 
unreported variant was also predicted to be deleterious, with an amino acid substitution from 
arginine to isoleucine at the 183 protein position. One individual in this study was observed to 
carry this variant. The third unreported CMPK1 missense variant was detected in five individuals 
and is predicted to affect the 192 protein position, substituting an asparagine residue for a lysine 
residue. This variant was predicted to be tolerated. The remaining four variants detected in 
individuals for this kinase were listed in the SNP database. The variant rs80046781 
(NM_016308.2:c.196G>T) was detected in 9 individuals and is predicted to be deleterious, 
yielding a 1.8% (9/498) frequency of this variant. A second previously reported variant, 
rs35687416 (NM_016308.2:c.240G>T) was also predicted to be deleterious, with 11 individuals 
exhibiting this variant (2.2% frequency, 11/498). The variant rs139782187 
(NM_016308.2:c.498G>T) was detected in one individual and was predicted to be deleterious. 
Finally, the fourth variant rs72553947 (NM_016308.2:c.344A>G) was predicted to be tolerated 
and was found in four individuals. Overall, the frequency of individuals exhibiting deleterious 





Table 7. CMPK1 missense variants detected in 34 clinical trial participants.  
 
 PGK1 genetic variants detected in two clinical trial participants. L-Fd4C-DP, a cytidine 
diphosphate analog like FTC-DP has been shown to be phosphorylated by PGK1 to form 3TC-
TP, a nucleotide triphosphate that competitively inhibits HIV reverse transcriptase [10]. We 
detected one previously unreported variant and one previously reported variant in PGK1. Neither 
variant was predicted to be deleterious.  
 
 








Exon Sift PolyPhen dbSNP ID Variant 
Frequency 
G>G/T het 605 433 145 A/S 5/11 tolerated(0.16) benign(0.023) 
 
0.2% (1/498) 
G>A/A hom 355 183 61 M/I 3/11 tolerated(0.1) benign(0.062) rs11541568 0.2% (1/498) 
 





 This study identifies and proposes genetic variants in candidate kinases for FTC 
activation, hypothesizing DCK and TK1 to phosphorylate FTC to FTC-MP, CMPK1 to 
phosphorylate FTC-MP to FTC-DP, and PGK1 to phosphorylate FTC-DP to FTC-TP, the 
pharmacologically active anabolite of FTC. In this work, we detected six previously unreported 
variants across these kinases. Further, we contribute more unreported variants to the growing 











Exon Sift PolyPhen dbSNP ID Variant 
Frequency 
G>G/T 345 196 66 A/S 2/6 deleterious(0) possibly_damaging(0.901) rs80046781 (9/498) 





G>G/T 697 548 183 R/I 4/6 deleterious(0) probably_damaging(0.998) 
 
(1/498) 
G>G/T 389 240 80 Q/H 2/6 deleterious(0) benign(0.31) rs35687416 (11/498) 
G>G/A 468 319 107 E/K 3/6 deleterious(0.01) benign(0.023) rs72553946 (1/498) 
G>G/T 647 498 166 R/S 4/6 deleterious(0) probably_damaging(0.999) rs139782187 (1/498) 
A>A/G 493 344 115 N/S 3/6 tolerated(0.84) benign(0.001) rs72553947 (4/498) 





genes that encode the TFV-activating kinases AK2, CKM, PKM, and PKLR, we detected 11 
previously unreported variants across these kinases. In the kinases DCK, TK1, CMPK1, and 
PGK1, the enzymes proposed to activate FTC, we detected six previously unreported variants. 
The analysis implemented in this study conformed to the American College of Medical Genetics 
and Genomics clinical laboratory standards for next-generation sequencing in order to increase 
confidence in the variants we detected [11]. This analysis has been previously described [5].  
  
 Focusing on AK2, the kinase we have previously demonstrated to phosphorylate TFV to 
TFV-MP, displayed three previously reported genetic variants upon sequencing for this gene. The 
variant rs138577419 was detected in one individual in this study, yielding a frequency of 0.2% 
(1/498). Comparing this frequency to the overall frequency listed in the Exome Aggregation 
Consortium (ExAC), a large-scale aggregation of human genomic data including over 60,000 
individuals [12], ExAC reports a frequency of 0.2%. Four of the seven subpopulations reported 
frequencies, with the non-Finnish European reporting 0.4%, African reporting 0.1%, African 
reporting 0.02%, and the sub-population Other reporting 0.5% frequency of this variant. A second 
previously reported variant, rs12116440 was detected in two individuals in this study, exhibiting 
a 0.4% frequency. This frequency is lower than the overall reported frequency for this variant 
reported in the ExAC database, which was 0.7%. This variant was detected in all sub-populations 
except for the East Asian subpopulation, which showed no frequency for this variant. This variant 
was also detected in one individual in a previous genotyping study carried out by our lab [5]. The 
third variant detected for AK2 that has been previously reported, rs61750965 also displayed a 
0.4% (2/498) frequency in this study. A previous study sequencing this kinase carried out by our 
lab also detected this variant in one individual [5]. This variant is reported at an overall frequency 
of 0.4% in the ExAC database, with all sub-populations reporting frequencies for this variant. Of 
the subpopulation frequencies reported for this variant, the highest reported is in the South Asian 
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 In DCK, one of two candidate kinases hypothesized to phosphorylate FTC to FTC-MP,  
DCK, three variants detected in our study have been previously reported in the SNP database.  
The variant rs67437265 was detected in six individuals in this study, with a frequency of 1.2% 
(6/498). Comparing this frequency to data reported by ExAC, we find that the overall population 
frequency for this variant is 1.9%. This includes African, East and South Asian, Latino, and 
European populations. Another previously reported variant, rs66878317 was detected in one 
individual, yielding a 0.2% frequency in this study. The frequency for this variant reported in 
ExAC was also reported at 0.2% across all populations, with East Asian and Finnish European 
populations included in the ExAC database reporting 0% frequency and African populations 
reporting 2.8% frequency. The last previously reported variant rs144479260 was reported in the 
ExAC database at 0.015% frequency, with only non-Finnish European (0.02% frequency), 
Finnish European (0.015% frequency), and Latino (0.017% frequency) populations reporting 
frequencies for this variant. These frequencies are lower than what was detected for this variant in 
this study, with one individual (0.2%, 1/498) exhibiting this variant. Sequencing this population 
for missense variants in DCK identified one previously undetected variant that was predicted to 
be deleterious. This variant translates to a mutation at the 93 protein position, reported to be 
located in an alpha helix and four amino acids away from a substrate binding site at the 97th 
amino acid [13]. The substitution from serine to phenylalanine reported at this position (S93F), 
changes the residue from a polar, uncharged, and relatively small side chain on the serine to a 
large, hydrophobic benzene ring on the resulting phenylalanine. This substitution coupled with 




Sequencing for the gene encoding CMPK1, four variants detected were found to be 
reported in the SNP database. The variant rs80046781 was detected in 9 individuals, however no 
reported frequency was available in the ExAC database. Predicted to result in a deleterious 
functional impact for this kinase, the genetic variant rs80046781 translates to the amino acid 
substitution at the 66 protein position A66S. This position is three amino acids away from a 
reported nucleotide monophosphate binding domain [14] and the amino acid substitution changes 
from a hydrophobic side chain in alanine to a polar side chain in serine. In vitro studies using this 
purified enzyme have been previously carried out investigating CMPK1 activity on another 
deoxycytidine analog, 2’,2’-difluorodeoxycytidine and have demonstrated activity kinase activity 
toward the monophosphorylated form of this compound [14]. Taken together, the nucleotide 
binding domain location, amino acid substitution, and demonstrated nucleotide analog 
phosphorylation information available for this kinase and the genetic variant detected could 
provide an explanation for why this variant is predicted to negatively impact protein function. A 
second previously reported variant rs35687416 was also predicted to be deleterious, with 11 
individuals exhibiting this variant (2.2% frequency, 11/498). Comparing this frequency to the 
frequency of this variant as reported in the ExAC database, all sub-populations included in the 
database exhibit frequency for this variant, resulting in an overall 4.5% frequency. The two sub-
populations displaying the highest frequency for this variant were East Asian, with 12% 
frequency and Finnish European with 6.7% frequency. The variant rs72553947 was detected in 
four individuals, resulting in a 0.8% frequency (4/498). This frequency is close to the overall 
frequency reported in the ExAC database, which reported a frequency across all populations at 
0.6%. All populations reported frequencies for this variant, with the population reporting the 
highest frequency at 3.1% being the East Asian population. The fourth previously reported 
variant for CMPK1 was detected in one individual in our study and was reported in the ExAC 
database at a frequency of less than 0.001%. Only one subpopulation included in the database 
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reported frequencies for this variant, with the African subpopulation presenting a 0.001% 
frequency for this reported variant.  
 
 The candidate kinase for phosphorylation of FTC-DP to FTC-TP, PGK1, exhibited one 
genetic variant rs11541568 included in the SNP database. This variant was detected in one 
individual and reported at an overall frequency of 0.001% in the ExAC database. The African 
subpopulation included in the database was the only one to report frequency of this variant, 
showing a frequency of 0.1% within that sub-population. This variant was not predicted to be 
deleterious, likely because of its location. Resulting in an amino acid mutation of M61I, this 
residue is not near any catalytic sites or nucleotide binding sites [15].   
 
In sequencing the kinases DCK, TK1, CMPK1, and PGK1, we are suggesting a pathway 
for emtricitabine activation. The kinases in this study predicted to phosphorylate emtricitabine 
need to be validated for activity in vitro toward emtricitabine and its phosphorylated anabolites, 
despite previously demonstrated activity toward other cytidine analogs. The predicted functional 
impact of the identified variants in these kinases also ultimately requires confirmation. Purified 
protein assays using site-directed mutagenesis would be beneficial toward confirmation of this 
predicted diminished activity.  
 
 The variants we have identified for TFV activation build further upon the concept we 
have previously put forth that protection against HIV infection using PrEP may yield inter-
individual results. Observation of previously unreported genetic variants in the kinases AK2, 
CKM, PKM, and PKLR contribute to the notion that there could be a genetic basis for variation 
in TFV phosphorylation and therefore protection from HIV. Functional deleterious predictions of 
three previously unreported genetic variants in CKM and two previously unreported genetic 
variants in PKLR bolster this concept. Further, the pathway of emtricitabine activation and the 
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resulting variants from the kinases we have proposed adds another element that could contribute 
to the variation in efficacy of PrEP despite adherence. Continuing to build upon the knowledge of 
variants in the kinases shown to activate TFV as well as addressing FTC phosphorylation 
encompasses all components of current FDA-approved PrEP formulations, allowing for a fuller 
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Chapter 4: Imaging tenofovir and tenofovir diphosphate using matrix assisted laser 
desorption ionization mass spectrometry imaging. 
 
Abstract 
A method to image tenofovir and its phosphorylated anabolite tenofovir diphosphate using matrix 
assisted laser desorption/ionization coupled to mass spectrometry has been developed. To detect 
tenofovir and tenofovir diphosphate, four different matrices were tested in both positive and 
negative ionization modes. Moving forward with the matrices generating the best sensitivity for 
each compound, α-hydroxycinnamic acid was used to detect tenofovir and 9-aminoacridine was 
used to detect tenofovir diphosphate. TFV was detected at the highest spotted concentration of 10 
µM and the lowest detectable spotted concentration of 125 nM. For TFV-DP detection, the 
highest spotted concentration was 10 µM and the lowest detectable spotted concentration at 78 
nM. This novel method can be applied to image tenofovir in tissue and detect tenofovir 
diphosphate using MALDI-MS.  
 
Introduction 
Along with being approved for use in HIV treatment, the nucleotide reverse transcriptase 
inhibitor tenofovir (TFV) is approved for and continues to be explored as a pharmacological 
approach toward protection from HIV infection [1-3]. Known as HIV pre-exposure prophylaxis, 
or PrEP, this strategy involves an HIV-uninfected individual taking TFV to prevent HIV 
infection. Currently, the only FDA approved route of administration of TFV for PrEP is oral [3], 
but topical routes of administration are under active investigation in HIV-susceptible tissues [4, 5, 
6]. 
In order to become pharmacologically active, TFV must be phosphorylated 
intracellularly. A prior study done by our laboratory has shown TFV to be phosphorylated to 
tenofovir-monophosphate (TFV-MP) by adenylate kinase 2 in peripheral blood mononuclear cells 
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(PBMC), vaginal, and colorectal tissue [7]. The active TFV anabolite, however, is tenofovir-
diphosphate (TFV-DP). A nucleotide triphosphate analog, TFV-DP competitively inhibits HIV 
reverse transcriptase and prevents viral DNA replication [1]. TFV-DP is formed by 
phosphorylation of TFV-MP by creatine kinase, muscle in colorectal tissue [7]. In PBMC and 
vaginal tissue, TFV-MP has been shown to be phosphorylated by pyruvate kinase, liver and red 
blood cell and pyruvate kinase, muscle to form TFV-DP [7].  
 Taken together, the compartment specificity of TFV activation demonstrated in our 
previous work and investigations of the efficacy of topical PrEP formulations call for a deeper 
understanding of TFV tissue pharmacokinetics. TFV and TFV-DP concentrations have been 
examined in compartments vulnerable to HIV infection such as rectal, vaginal, and cervical 
tissues [6, 8, 9, 10]. While these studies have been helpful in confirming and measuring the 
amount of drug able to penetrate HIV-susceptible tissues, quantifications of TFV and TFV-DP 
are measured using liquid chromatography coupled to tandem mass spectrometry (LC/MS) from 
tissue homogenates [6, 9]. Measurements from homogenates are only able to provide a 
quantification of drug that is essentially the amount found throughout the tissue. Using these 
methods to examine TFV and TFV-DP in tissues, any drug distribution information is lost when 
the tissue is homogenized.  
 Along with LC/MS methods, another way drug is measured in tissue is using whole body 
autoradiography  [11]. Currently the standard technique used in preclinical studies to determine 
drug distribution [12], this technique this technique uses radioactivity incorporated into a 
molecule of interest. This is then administered in an animal model and the resulting emissions are 
detected and imaged. Despite the ability to provide spatial distribution information, however, this 
technique is limited in that it is only able to detect the distribution of the radioactive compound. 
Because of this, it is possible that metabolites of the drug will not be detected.   
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The two-dimensional nature in which data are collected using matrix assisted laser 
desorption/ionization coupled to imaging mass spectrometry is able to yield drug distribution 
information in tissue [13]. Like LC/MS methods, detection of compounds and any metabolites is 
possible due to analysis using the mass spectrometer. Similar to inquiry using whole body 
autoradiography spatial distribution information is attainable due to the movement of the sample 
plate in MALDI-IMS. In this study, we harness this technology and develop a method to detect 
TFV and its phosphorylated anabolite TFV-DP using a MALDI-Orbitrap XL mass spectrometer 
[14].  
TFV has previously reported to be detected using MALDI technology in a IR-laser 
matrix assisted laser desorption electrospray ionization (IR-MALDESI) [15]. Using this 
technique, distribution of TFV in cervical tissues was investigated. More conventional uses of 
MALDI have also been applied to detect TFV. TFV has been detected using MALDI coupled to a 
triple quadrupole mass spectrometer in plasma from HIV-infected adults [16]. This study 
develops an assay for the detection of TFV and TFV-DP using MALDI coupled to an LTQ 
Orbitrap XL mass spectrometer. Not only are we able to detect the parent drug TFV, but we also 
report detection of its phosphorylated active metabolite TFV-DP using MALDI. This technique 
can be applied to gain spatial distribution information of these anti-HIV drugs and inform future 





Experimental/Materials and methods  
Materials. Solvents for the drug standards and matrix solutions were OptimaTM uHPLC grade 
water, methanol, acetonitrile, and ethanol (200 proof) from DeconTM Labs were all obtained from 
Fisher Scientific (Waltham, MA). Trifluoroacetic acid was purchased from Sigma-Aldrich (St. 
Louis, MO). The matrices tested were obtained as follows: α-cyano-4-hydroxycinnamic acid 
(CHCA), 9-aminoacridine (9AA), anthranilic acid (AA), nicotinic acid (NA), and 3-
hydroxypicolinic acid (3HPA) were all procured from Sigma-Aldrich (St. Louis, MO). The 
matrix compound 2,5-dihydroxybenzoic acid (DHB), 99% from ACROS OrganicsTM was 
purchased from Fisher Scientific (Waltham, MA). Tenofovir was obtained from the NIH AIDS 
Reagent Program, Division of AIDS (DAIDS), NIAID, NIH. Tenofovir diphosphate was 
purchased as a triethylamine salt from Toronto Research Chemicals (North York, ON, Canada). 
Drug standard preparation. TFV and TFV-DP were diluted separately using uHPLC grade water 
to 10 mM as a starting concentration and further diluted for MALDI-MS analysis. Solutions were 
stored at -20° C. 
Matrix solution preparation. Matrix solutions that were investigated for their suitability to detect 
TFV or TFV-DP are detailed in Table 1. Following preparation of matrix solutions, all solutions 





Matrix Used Concentration (mg/mL) Solvent 
α-cyano-4-hydroxycinnamic acid 10 70% acetonitrile, 30% water, 0.3% trifluoroacetic acid 
9-aminoacridine 10 90% ethanol, 10% water 
anthranilic acid, nicotinic acid, 
diammonium citrate 6.17, 5.54, 12.44 55% water, 45% acetonitrile 
3-hydroxypicolinic acid 40 70% acetonitrile, 30% water, 0.3% trifluoroacetic acid 
2,5-dihydroxybenzoic acid 40 70% acetonitrile, 30% water, 0.3% trifluoroacetic acid 
Table 1. Matrix solutions investigated for suitability to detect TFV or TFV-DP.  
 
Sample preparation. To determine optimal settings for the detection of TFV and TFV-DP, drug 
standards were mixed with matrix solution at a 1:1 ratio and pipetted onto a 384 spot steel target 
plate. Optimal mass spectrometer settings to detect TFV were determined using a 10 mg/mL 
concentration of CHCA and a final TFV concentration of 10 µM. TFV-DP detection was 
optimized using a 10 mg/mL concentration of 9-AA matrix mixed with TFV-DP standard to 10 
µM. To establish a method for imaging TFV and TFV-DP on tissue, 1.5 µL dilutions of each drug 
standard were pipetted onto the steel target plate. Serial dilutions at 10, 5, 2.5, 1.25, 0.625, 
0.3125, 0.156, and 0.78 µM of TFV and TFV-DP were spotted at a volume of 1.5 µL. To ensure 
specific detection of each compound, 1.5 µL of water (as vehicle) was also pipetted and analyzed 
for the presence of TFV or TFV-DP.  
LTQ Orbitrap XL analysis. A MALDI-MS/MS method was developed and optimized to detect 
TFV and TFV-DP using a MALDI source coupled to a LTQ Orbitrap XL mass spectrometer 
(Thermo Scientific, Pittsburgh, PA). Laser energy for ionization of TFV and TFV-DP in the 
MALDI source was used at 20 µJ. Automatic gain control target settings to use the Orbitrap mass 
analyzer (FTMS) were set at 1 X 106 ions for a full MS scan, 5 X 104 ions for a selected ion 
monitoring (SIM) scan, and 2 X 105 ions for MS/MS analysis. The following parameters were 
specified on the FTMS mass analyzer for TFV detection: positive ionization mode, mass 
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resolution at 100,000. Normalized collision energy (NCE) using collision-induced dissociation 
for generation of TFV fragment ions was tested at 15%, 20%, and 35%. To identify TFV, the 
transition 288.08560176 (176.09191 ± 5 ppm)was monitored. TFV-DP detection was achieved 
using the following parameters specified: negative ionization mode, mass resolution at 100,000. 
To generate fragment ions for TFV-DP identification, collision-induced dissociation was 
performed. NCE at 10%, 15%, and 20% were tested. Identification of TFV-DP was determined 
by monitoring the transition 446.00372348 (348.0975 ± 5 ppm). Spotted drug standards were 
imaged with the camera on the MALDI source using Thermo Tune Plus software (Thermo 
Scientific, Pittsburgh, PA). Raster size of each laser step was used at 400 µm step size.   
 
Data processing and analysis. ImageQuest software (Thermo Scientific, Pittsburgh, PA) was 
used to visualize the fragment ions generated from TFV or TFV-DP detection. To determine the 
spatial distribution of TFV, the mass to charge ratio at 176.09296 was extracted from the spectra 
collected using a narrow mass tolerance window of 5 ppm. TFV-DP distribution was localized 
using the mass to charge ratio at 348.0975 with the same mass range window at 5 ppm.  
 
Results 
TFV detection is achieved using CHCA matrix while TFV-DP is ionized using 9AA. Several 
matrices were tested for their suitability to detect either TFV or TFV-DP. Of all the matrices 
tested, only CHCA was able to ionize TFV at the starting concentration of the drug standard we 
tested at 10 µM. Using the CHCA matrix, TFV was ionized in positive ion mode, yielding a 
protonated parent ion m/z ratio at 288.08560 ± 5 ppm. To detect TFV-DP, all four matrices were 
also tested. The matrix 9AA was the only matrix that allowed for detection of TFV-DP at 10 µM. 
The 9AA matrix ionized TFV-DP in negative ion mode, generating a parent ion at m/z = 




Normalized collision energy of 35% provides optimal fragmentation for TFV detection with 
CHCA matrix using the LTQ Orbitrap XL. Using the matrix CHCA to ionize TFV, generation of 
fragment ions of TFV was investigated by performing collision-induced dissociation at 
incrementally higher NCE (Figure 1). At 15% NCE, no fragmentation of TFV (m/z = 288.08378) 
was observed. Increasing NCE to 20% yielded fragmentation of TFV, producing fragment ions at 
m/z = 176.09188 and m/z = 206.10225. Water loss of TFV at m/z = 270.07345 was also 
observed. NCE at 35% generated the highest abundance of the fragment ion at m/z = 176.09191 




Figure 1. Total ion chromatogram fragmentation spectra of TFV at increasing normalized 
collision energies (NCE). Collision-induced dissociation was used to generate fragment ions to 
identify TFV. NCE at 15%, 20%, and 35% were tested. NCE at 15% shows no fragmentation of 
TFV. The NCE at 35% yielded the greatest intensity for the fragment ion of TFV using the 
transition at m/z = 288.08560176. 
 
Spatial distribution of TFV on a steel target plate can be determined using MALDI-MS imaging. 
Following optimization of TFV detection using CHCA matrix, detection methods were applied 
toward investigating TFV localization on a steel target plate. TFV standard at 10 µM final 
concentration mixed in a 1:1 ratio with CHCA matrix can be visualized when using the extracted 
fragment ion at m/z = 176 (Figure 2). All spectra included in the images in the middle panel of 
figure 2 contain detectable peaks at m/z = 176.09296 with a 5 ppm mass tolerance window. To 
ensure specific identification of TFV, water was combined in a 1:1 ratio with CHCA matrix 
solution. No spectra collected in the water sample had a peak at m/z = 176.09296 ± 5 ppm. On a 
steel target plate, TFV was detected at the highest spotted concentration of 10 µM and the lowest 





















































































Figure 2. Distribution of TFV standard on a steel target plate using extracted ion MS/MS data. 
(A) TFV drug standard solution is mixed 1:1 with CHCA matrix solution, with 1.5 µL of the 
resulting solution pipetted onto a steel target plate. The resulting molecular image shows 
localization of TFV using the fragment ion at m/z = 176.09296 ± 5 ppm. The spectrum displayed 
is an average spectra across the entire sample. (B) Water is mixed in a 1:1 ratio with CHCA 
matrix solution. A volume of 1.5 µL of the resulting mixture is pipetted onto a steel target plate 
for MALDI-IMS analysis. When m/z = 176.09296 ± 5 ppm is extracted from the resulting spectra 
of this dataset, this peak is absent from all spectra collected.  
 
Differences in TFV abundance can be detected using MALDI-MS imaging. This technique can 
demonstrate differences in abundance of tenofovir when a drug standard is pipetted onto a glass 
slide. Following application with CHCA matrix as described above, drug standards at 10 µM, 5 
µM, and 2.5 µM were detected at differing intensities. The fragment ion peak at 288.0856  
176.09296 ± 5 ppm was detected at 933.9 intensity for the 2.5 μM drug standard. At 5 μM and 10 





Figure 3. Detection of TFV drug standard at different concentrations shows differences in 
intensity. Depicted in the figure above is an optical image of the three areas in which the drug 
standard was spotted and subsequently coated with CHCA matrix. The middle panel shows a 
molecular image of all collected spectra from which the fragment ion 288.08560176.06296 was 
detected. Finally, the fragmentation spectra in the rightmost panel show increasing intensity of 
the peak at 176.09296 ± 5 ppm at increasing concentrations of TFV drug standard are imaged.  
 
Detection of TFV in cervical biopsy. TFV gel (40 mg of TFV) in water with edetate disodium, 
citric acid, glycerin, methylparaben, propylparaben, and hydroxyethycellulose was applied 
topically to vaginal tissue of a clinical trial participant. After application, five hours were allowed 
to elapse and a cervical biopsy was collected. We are able to detect TFV in the biopsy and 




Figure 4. TFV distribution in a cervical biopsy is detected in a heterogeneous manner. TFV is not 
detected throughout the biopsy in a homogenous manner. Instead, we observe TFV localization in 
one area of the biopsy but not its entirety.  
 
Normalized collision energy of 20% provides optimal fragmentation for TFV-DP detection with 
9AA matrix using the LTQ Orbitrap XL. Subsequent to determining the suitability of 9AA as an 
effective matrix to ionize TFV-DP, generation of fragment ions of TFV-DP was investigated as 
with TFV (Figure 3). At 15% NCE, no fragmentation of TFV-DP (m/z = 446.00281) was 
observed. Increasing NCE to 20% yielded fragmentation of TFV-DP, producing a fragment ions 
at m/z = 348.02608 from the parent ion at m/z = 446.00249. NCE at 22% generated the highest 
abundance of the fragment ion at m/z = 348.02379 from the parent TFV ion at m/z = 445.99881. 
The m/z = 445.99881 is within the mass tolerance window of 5 ppm. NCE higher than 22% was 





Figure 4. TFV-DP fragmentation at normalized collision energies (NCE) of 15%, 20%, and 22%. 
No fragmentation of TFV-DP is observed at 15% NCE. The NCE at 22% yielded the greatest 
intensity for the fragment ion of TFV-DP using the transition at m/z = 445.99881348.02379. 
 
Spatial distribution of TFV-DP on a steel target plate is presented using MALDI-MS imaging. 
Detection methods of TFV-DP, the active anabolite of TFV, were applied toward investigating 
TFV-DP distribution on a steel target plate. A TFV-DP standard solution at 10 µM final 
concentration mixed in a 1:1 ratio with 9AA  matrix can be visualized when using the extracted 
fragment ion at m/z = 348 (Figure 3). Heterogeneous TFV-DP distribution was observed in the 
spotted standard, with TFV-DP unable to be detected uniformly throughout the sample. Water 
was combined in a 1:1 ratio with 9AA matrix solution as a negative control. No spectra collected 
in the water sample had a peak at m/z = 348.02379 ± 5 ppm. For TFV-DP detection, the highest 





Figure 5. TFV-DP drug standard on a steel target plate visualized using extracted ion MS/MS 
data. (A) TFV-DP drug standard is combined with 9AA matrix solution in a 1:1 ratio, with 1.5 µL 
of the resulting solution pipetted onto a steel target plate. Localization of TFV-DP using the 
fragment ion at m/z = 348.02379 ± 5 ppm is demonstrated in the middle panel. The spectrum 
displayed is an average spectra across the entire spot scanned by the laser. (B) Water is added in 
1:1 ratio to 9AA matrix solution. Extraction of the TFV-DP fragment ion at m/z = 348.02379 ± 5 
ppm yields no peaks from the dataset collected for this spot.  
 
Discussion 
This method presents a  technique to examine TFV and its pharmacologically active 
anabolite TFV-DP. We are able to establish imaging of TFV using CHCA matrix and detection 
using a MALDI source coupled to an LTQ-Orbitrap mass spectrometer. Further, TFV-DP has not 
previously been reported to be detected using MALDI. We employ the matrix 9AA in negative 
ion mode to demonstrate detection of TFV-DP using MALDI-MS.  
In determining which matrices to test in order to best detect TFV, previous studies 
examining TFV using MALDI as well as the structure of TFV were taken into account. The 
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matrix CHCA was used to detect TFV in plasma in a previous study [16]. TFV mimics the 
structure of adenine monophosphate, rendering it a nucleotide monophosphate analog. The matrix 
3HPA has been reported to ionize oligonucleotides [17] using time-of-flight mass spectrometry. 
Ionization of oligonucleotides by 3HPA made it a promising candidate for ionizing TFV, a 
nucleotide monophosphate analog. Along with CHCA and 3HPA, the matrix DHB was also 
tested. DHB is a widely used matrix for ionizing small molecules such as peptides and lipids [18, 
19], however given the common ionization efficiency of DHB it was still investigated as a matrix 
for ionizing TFV. Ultimately however, CHCA proved to be the most suitable matrix for detecting 
TFV using the method we developed.  
No prior studies reporting detection of TFV-DP by MALDI have been reported. 
However, there have been studies reporting nucleotide triphosphate and nucleotide triphosphate 
analog detection using MALDI coupled to either time-of-flight mass spectrometers or fourier 
transform ion cyclotron resonance mass spectrometers [20, 21, 22]. One study reported the 
detection of azetidine-triphosphate, another HIV reverse transcriptase inhibitor using a comatrix 
of anthranilic acid and nicotinic acid [20] in PBMC. Other studies have reported detection and 
subsequent imaging of the endogenous nucleotide triphosphate adenosine triphosphate (ATP) in 
rat brain and in kidney [21, 22]. To detect ATP, the matrix 9AA was used in both studies. The 
structural similarity between ATP and TFV-DP made the matrix 9AA a good candidate for 
allowing for TFV-DP detection. This similarity is likely also what made 9AA the most sensitive 
matrix for TFV-DP detection of the matrices tested. 
Along with optimizing the detection of TFV and TFV-DP using an LTQ Orbitrap, 
imaging these two compounds allows for application of this technique toward investigating the 
spatial distribution of these drugs in tissue. This work is the first to report molecular imaging of 
TFV and TFV-DP using MALDI-IMS with an LTQ-Orbitrap XL mass spectrometer. Taken with 
the drug distribution information that MALDI yields, the high resolution accurate mass 
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capabilities provided by the Orbitrap aid in providing accurate mass measurements of TFV and 
TFV-DP.  
Future experiments applying this technique can address the compartment specificity of 
TFV activation in the HIV susceptible PBMC, vaginal, and colorectal tissues. These studies 
would provide spatial distribution information regarding drug localization and activation. 
Examining the distribution of TFV would be able to direct PrEP studies regarding the penetration 
of TFV in tissue. This information would build upon current investigations on the effectiveness of 
PrEP. In the case of imaging TFV-DP in tissue, this would yield information regarding the 
activation of TFV. Taken together, the spatial distribution information of both TFV and TFV-DP 
in tissue that this method could provide would yield a deeper understanding of PrEP efficacy 
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Chapter 5: Conclusions 
 Comprising the only FDA-approved HIV pre-exposure prophylaxis regimen 
Truvada ®, the nucleoside/nucleotide reverse transcriptase inhibitors tenofovir and 
emtricitabine require further studies regarding their activation. This is especially 
necessary since no clinical studies reporting full protection against HIV infection have 
yet been recorded. Participant adherence to the drug regimen has been shown to play a 
major role in this gap in protection, however, taking adherence into account has been able 
to yield 92% protection against HIV infection at most [1]. The studies carried out here 
begin to address possible sources of variation that could affect PrEP activation.  
 In looking for genetic variants in the genes that encode the kinases adenylate 
kinase 2, creatine kinase, muscle, pyruvate kinase, muscle, and pyruvate kinase, liver and 
red blood cell, we build upon previous studies identifying the phosphorylation scheme of 
tenofovir [2]. The genetic variants detected in the studies in Chapters 2 and 3, along with 
their predicted functional impacts, provide a starting point for examining sources of 
differences in inter-individual tenofovir phosphorylation. Depending on their functional 
impact, these genetic variants could negatively impact tenofovir phosphorylation, leading 
to compromised protection from HIV infection.  
 Along with discovering genetic variants in kinases that play a role in tenofovir 
phosphorylation, the emtricitabine phosphorylation pathway has also been proposed. In 
Chapter 3, we put forward a phosphorylation scheme for emtricitabine activation. Genetic 
variants in thymidine kinase 1, deoxycytidine kinase, cytidine monophosphate kinase 1, 
and phosphoglycerate kinase 1 have been discovered, but their predicted functional 
impact must yet be interrogated using in vitro studies.  
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 Tantamount to the identification of tenofovir activating kinases is the discovery of 
their compartment-specific manner of tenofovir phosphorylation. While adenylate kinase 
2 was found to phosphorylate tenofovir to tenofovir-monophosphate across peripheral 
blood mononuclear cells, colorectal tissue, and vaginal tissue, creatine kinase, muscle 
was demonstrated to phosphorylate tenofovir-monophosphate to tenofovir-diphosphate in 
colorectal tissue but not in vaginal tissue or peripheral blood mononuclear cells. The 
kinases pyruvate kinase, muscle and pyruvate kinase, liver and red blood cell were found 
to generate tenofovir-diphosphate in vaginal tissue and peripheral blood mononuclear 
cells but not in colorectal tissue. This compartment specificity demonstrates a need for 
the spatial distribution information of tenofovir and tenofovir activation, addressed by the 
method developed in Chapter 4. Using matrix-assisted laser desorption/ionization 
coupled to mass spectrometry, this method is able to preserve distribution information by 
analyzing tissue slices.  
 Taken together, these pharmacogenetic and imaging approaches toward 
understanding tenofovir and emtricitabine activation provide sources of possible 
differences in HIV PrEP trial outcomes. These data begin to provide a shift in the current 
understanding of HIV drug metabolism by demonstrating drug activation in colorectal 
and vaginal tissues, possible sources of HIV transmission. These studies can be used to 
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